[
["index.html", "fulltext manual Chapter 1 fulltext manual 1.1 Info 1.2 Citing fulltext 1.3 Installation", " fulltext manual 2017-12-19 - fulltext v0.1.9.9621 Chapter 1 fulltext manual An R package to search across and get full text for open access journals The fulltext package makes it easy to do text-mining by supporting the following steps: Search for articles Fetch articles Get links for full text articles (xml, pdf) Extract text from articles / convert formats Collect bits of articles that you actually need Download supplementary materials from papers 1.1 Info Code: https://github.com/ropensci/fulltext/ Issues: https://github.com/ropensci/fulltext/issues CRAN: https://cran.rstudio.com/web/packages/fulltext/ 1.2 Citing fulltext Scott Chamberlain &amp; Will Pearse (2017). fulltext: Full Text of ‘Scholarly’ Articles Across Many Data Sources. R package version 0.1.9.9621. https://github.com/ropensci/fulltext 1.3 Installation Stable version from CRAN install.packages(&quot;fulltext&quot;) Development version from GitHub devtools::install_github(&quot;ropensci/fulltext&quot;) Load library library(&#39;fulltext&#39;) "],
["intro.html", "Chapter 2 Introduction 2.1 User interface", " Chapter 2 Introduction 2.1 User interface Functions in fulltext are setup to make the package as easy to use as possible. The functions are organized around use cases: Search for articles Get full text links Get articles Get abstracts Pull out article sections of interest Because there are so many data sources for scholarly texts, it makes a lot of sense to simplify the details of each data source, and present a single user interface to all of them. "],
["data-sources.html", "Chapter 3 Data sources", " Chapter 3 Data sources Data sources in fulltext include: Crossref - via the rcrossref package Public Library of Science (PLOS) - via the rplos package Biomed Central arXiv - via the aRxiv package bioRxiv - via the biorxivr package PMC/Pubmed via Entrez - via the rentrez package Many more are supported via the above sources (e.g., Royal Society Open Science is available via Pubmed) We will add more, as publishers open up, and as we have time…See the master list here "],
["authentication.html", "Chapter 4 Authentication", " Chapter 4 Authentication Some data sources require authentication. Here’s a breakdown of how to do authentication by data source: BMC: BMC is integrated into Springer Publishers now, and that API requires an API key. Get your key by signing up at https://dev.springer.com/, then you’ll get a key. Pass the key to a named parameter key to bmcopts. Or, save your key in your .Renviron file as SPRINGER_KEY, and we’ll read it in for you, and you don’t have to pass in anything. Scopus: Scopus requires an API key to search their service. Go to https://dev.elsevier.com/index.html, register for an account, then when you’re in your account, create an API key. Pass in as variable key to scopusopts, or store your key under the name ELSEVIER_SCOPUS_KEY as an environment variable in .Renviron, and we’ll read it in for you. See ?Startup in R for help. Microsoft: Get a key by creating an Azure account at https://www.microsoft.com/cognitive-services/en-us/subscriptions, then requesting a key for Academic Knowledge API within Cognitive Services. Store it as an environment variable in your .Renviron file - see [Startup] for help. Pass your API key into maopts as a named element in a list like list(key = Sys.getenv('MICROSOFT_ACADEMIC_KEY')) Crossref: Crossref encourages requests with contact information (an email address) and will forward you to a dedicated API cluster for improved performance when you share your email address with them. https://github.com/CrossRef/rest-api-doc#good-manners--more-reliable-service To pass your email address to Crossref via this client, store it as an environment variable in .Renviron like crossref_email = name@example.com None needed for PLOS, eLife, arxiv, biorxiv, Euro PMC, or Entrez (though soon you will get better rate limtits with auth for Entrez) "],
["search.html", "Chapter 5 Search 5.1 Usage", " Chapter 5 Search Search is what you’ll likely start with for a number of reasons. First, search functionality in fulltext means that you can start from searching on words like ‘ecology’ or ‘cellular’ - and the output of that search can be fed downstream to the next major task: fetching articles. 5.1 Usage library(fulltext) List backends available ft_search_ls() #&gt; [1] &quot;arxiv&quot; &quot;biorxivr&quot; &quot;bmc&quot; &quot;crossref&quot; &quot;entrez&quot; #&gt; [6] &quot;europe_pmc&quot; &quot;ma&quot; &quot;plos&quot; &quot;scopus&quot; Search - by default searches against PLOS (Public Library of Science) res &lt;- ft_search(query = &quot;ecology&quot;) The output of ft_search is a ft S3 object, with a summary of the results: res #&gt; Query: #&gt; [ecology] #&gt; Found: #&gt; [PLoS: 41104; BMC: 0; Crossref: 0; Entrez: 0; arxiv: 0; biorxiv: 0; Europe PMC: 0; Scopus: 0; Microsoft: 0] #&gt; Returned: #&gt; [PLoS: 10; BMC: 0; Crossref: 0; Entrez: 0; arxiv: 0; biorxiv: 0; Europe PMC: 0; Scopus: 0; Microsoft: 0] and has slots for each data source: names(res) #&gt; [1] &quot;plos&quot; &quot;bmc&quot; &quot;crossref&quot; &quot;entrez&quot; &quot;arxiv&quot; &quot;biorxiv&quot; #&gt; [7] &quot;europmc&quot; &quot;scopus&quot; &quot;ma&quot; Get data for a single source res$plos #&gt; Query: [ecology] #&gt; Records found, returned: [41104, 10] #&gt; License: [CC-BY] #&gt; id #&gt; 1 10.1371/journal.pone.0001248 #&gt; 2 10.1371/journal.pone.0059813 #&gt; 3 10.1371/journal.pone.0155019 #&gt; 4 10.1371/journal.pone.0080763 #&gt; 5 10.1371/journal.pone.0150648 #&gt; 6 10.1371/journal.pcbi.1003594 #&gt; 7 10.1371/journal.pone.0102437 #&gt; 8 10.1371/journal.pone.0175014 #&gt; 9 10.1371/journal.pone.0166559 #&gt; 10 10.1371/journal.pone.0054689 "],
["links.html", "Chapter 6 Links 6.1 Usage", " Chapter 6 Links The ft_links function makes it easy to get URLs for full text versions of articles. You can for instance only use fulltext to pass DOIs directly to ft_links to get URLs to use elsewhere in your research workflow. Or you may want to search first with ft_search, then pass that output directly to ft_links. 6.1 Usage library(fulltext) List backends available ft_links_ls() #&gt; [1] &quot;bmc&quot; &quot;cogent&quot; &quot;copernicus&quot; &quot;crossref&quot; &quot;elife&quot; #&gt; [6] &quot;entrez&quot; &quot;frontiersin&quot; &quot;peerj&quot; &quot;plos&quot; You can pass DOIs directly to ft_links (res &lt;- ft_links(&#39;10.3389/fphar.2014.00109&#39;)) #&gt; &lt;fulltext links&gt; #&gt; [Found] 1 #&gt; [IDs] 10.3389/fphar.2014.00109 ... res$frontiersin #&gt; $found #&gt; [1] 1 #&gt; #&gt; $ids #&gt; [1] &quot;10.3389/fphar.2014.00109&quot; #&gt; #&gt; $data #&gt; $data$`10.3389/fphar.2014.00109` #&gt; $data$`10.3389/fphar.2014.00109`$xml #&gt; [1] &quot;http://journal.frontiersin.org/article/10.3389/fphar.2014.00109/xml/nlm&quot; #&gt; #&gt; $data$`10.3389/fphar.2014.00109`$pdf #&gt; [1] &quot;http://journal.frontiersin.org/article/10.3389/fphar.2014.00109/pdf&quot; #&gt; #&gt; #&gt; #&gt; $opts #&gt; list() Or search first (res1 &lt;- ft_search(query=&#39;ecology&#39;, from=&#39;entrez&#39;)) #&gt; Query: #&gt; [ecology] #&gt; Found: #&gt; [PLoS: 0; BMC: 0; Crossref: 0; Entrez: 138841; arxiv: 0; biorxiv: 0; Europe PMC: 0; Scopus: 0; Microsoft: 0] #&gt; Returned: #&gt; [PLoS: 0; BMC: 0; Crossref: 0; Entrez: 10; arxiv: 0; biorxiv: 0; Europe PMC: 0; Scopus: 0; Microsoft: 0] Then pass the output of that directly to ft_links (out &lt;- ft_links(res1)) #&gt; &lt;fulltext links&gt; #&gt; [Found] 5 #&gt; [IDs] ID_29242556 ID_29237449 ID_29237396 ID_29233178 ID_28805166 ... "],
["fetch.html", "Chapter 7 Fetch 7.1 Data formats 7.2 How data is stored 7.3 Usage", " Chapter 7 Fetch The ft_get function makes it easy to fetch full text articles. There are a few different ways to use ft_get: Pass in only DOIs - leave from parameter NULL. This route will first query Crossref API for the publisher of the DOI, then we’ll use the appropriate method to fetch full text from the publisher. If a publisher is not found for the DOI, then we’ll throw back a message telling you a publisher was not found. Pass in DOIs (or other pub IDs) and use the from parameter. This route means we don’t have to make an extra API call to Crossref (thus, this route is faster) to determine the publisher for each DOI. We go straight to getting full text based on the publisher. Use ft_search() to search for articles. Then pass that output to this function, which will use info in that object. This behaves the same as the previous option in that each DOI has publisher info so we know how to get full text for each DOI. Note that some publishers are available through other data sources, e.g., through Entrez’s Pubmed. ft_get is a bit complicated. These are just some of the hurdles we’re jumping over: Negotiating various user inputs, likely seeing new publishers we’ve not dealt with Dealing with authentication and trying to make it easier for users Users sometimes being at an IP address that has access to a publisher and sometimes not Caching results to avoid unnecessary downloads if the content has already been acquired Thus, expect some hiccups here, and please do report problems, and if a certain publisher is not supported yet. 7.1 Data formats You can specify whether you want PDF, XML or plaint text with the type parameter. It is sometimes ignored, sometimes used, depending on the data source. For certain data sources, they only accept one type. Details by data source/publisher: PLOS: pdf and xml Entrez: only xml eLife: pdf and xml Pensoft: pdf and xml arXiv: only pdf BiorXiv: only pdf Elsevier: pdf and plain Wiley: only pdf Peerj: pdf and xml Informa: only pdf FrontiersIn: pdf and xml Copernicus: pdf and xml Scientific Societies: only pdf Crossref: depends on the publisher other data sources/publishers: there are too many to cover here - will try to make a helper in the future for what is covered by different publishers 7.2 How data is stored This depends on what backend value you use. If you use the default (rds) we store all data in .rds files. These are binary compressed files that are specific to R. Because they are specific to R, you don’t want to use this option if part of your downstream workflow is using another tool/programming language. The three types are stored in differnt ways. xml and plain text are parsed to plain text then stored with whatever backend you choose. However, pdf is retrived as raw bytes and stored as such. Thus, we no longer write pdf files to disk. However, you can easily do that yourself with ft_extract() or yourself by using pdftools::pdf_text which accepts a file path to a pdf or raw bytes. 7.3 Usage library(fulltext) List backends available ft_get_ls() #&gt; [1] &quot;arxiv&quot; &quot;biorxiv&quot; &quot;bmc&quot; #&gt; [4] &quot;copernicus&quot; &quot;elife&quot; &quot;elsevier&quot; #&gt; [7] &quot;entrez&quot; &quot;frontiersin&quot; &quot;informa&quot; #&gt; [10] &quot;peerj&quot; &quot;pensoft&quot; &quot;plos&quot; #&gt; [13] &quot;scientificsocieties&quot; &quot;wiley&quot; The simplest approach is passing a DOI directly to ft_get (res &lt;- ft_get(&#39;10.1371/journal.pone.0086169&#39;)) #&gt; &lt;fulltext text&gt; #&gt; [Docs] 1 #&gt; [Source] R session #&gt; [IDs] 10.1371/journal.pone.0086169 ... res$plos #&gt; $found #&gt; [1] 1 #&gt; #&gt; $dois #&gt; [1] &quot;10.1371/journal.pone.0086169&quot; #&gt; #&gt; $data #&gt; $data$backend #&gt; NULL #&gt; #&gt; $data$path #&gt; [1] &quot;session&quot; #&gt; #&gt; $data$data #&gt; 1 full-text articles retrieved #&gt; Min. Length: 110717 - Max. Length: 110717 #&gt; DOIs: 10.1371/journal.pone.0086169 ... #&gt; #&gt; NOTE: extract xml strings like output[&#39;&lt;doi&gt;&#39;] #&gt; #&gt; $opts #&gt; $opts$doi #&gt; [1] &quot;10.1371/journal.pone.0086169&quot; #&gt; #&gt; $opts$basepath #&gt; [1] &quot;/Users/sckott/Library/Caches/R/fulltext&quot; #&gt; #&gt; $opts$type #&gt; [1] &quot;xml&quot; You can pass many DOIs in at once (res &lt;- ft_get(c(&#39;10.3389/fphar.2014.00109&#39;, &#39;10.3389/feart.2015.00009&#39;))) #&gt; &lt;fulltext text&gt; #&gt; [Docs] 2 #&gt; [Source] R session #&gt; [IDs] 10.3389/fphar.2014.00109 10.3389/feart.2015.00009 ... res$frontiersin #&gt; $found #&gt; [1] 2 #&gt; #&gt; $dois #&gt; [1] &quot;10.3389/fphar.2014.00109&quot; &quot;10.3389/feart.2015.00009&quot; #&gt; #&gt; $data #&gt; $data$backend #&gt; NULL #&gt; #&gt; $data$path #&gt; [1] &quot;session&quot; #&gt; #&gt; $data$data #&gt; $data$data$`10.3389/fphar.2014.00109` #&gt; [1] &quot;&lt;?xml version=\\&quot;1.0\\&quot; encoding=\\&quot;UTF-8\\&quot; standalone=\\&quot;no\\&quot;?&gt;\\r\\n&lt;!DOCTYPE article PUBLIC \\&quot;-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN\\&quot; \\&quot;journalpublishing.dtd\\&quot;&gt;\\r\\n&lt;article xmlns:mml=\\&quot;http://www.w3.org/1998/Math/MathML\\&quot; xmlns:xlink=\\&quot;http://www.w3.org/1999/xlink\\&quot; article-type=\\&quot;review-article\\&quot;&gt;\\r\\n&lt;front&gt;\\r\\n&lt;journal-meta&gt;\\r\\n&lt;journal-id journal-id-type=\\&quot;publisher-id\\&quot;&gt;Front. Pharmacol.&lt;/journal-id&gt;\\r\\n&lt;journal-title&gt;Frontiers in Pharmacology&lt;/journal-title&gt;\\r\\n&lt;abbrev-journal-title abbrev-type=\\&quot;pubmed\\&quot;&gt;Front. Pharmacol.&lt;/abbrev-journal-title&gt;\\r\\n&lt;issn pub-type=\\&quot;epub\\&quot;&gt;1663-9812&lt;/issn&gt;\\r\\n&lt;publisher&gt;\\r\\n&lt;publisher-name&gt;Frontiers Media S.A.&lt;/publisher-name&gt;\\r\\n&lt;/publisher&gt;\\r\\n&lt;/journal-meta&gt;\\r\\n&lt;article-meta&gt;\\r\\n&lt;article-id pub-id-type=\\&quot;doi\\&quot;&gt;10.3389/fphar.2014.00109&lt;/article-id&gt;\\r\\n&lt;article-categories&gt;\\r\\n&lt;subj-group subj-group-type=\\&quot;heading\\&quot;&gt;\\r\\n&lt;subject&gt;Pharmacology&lt;/subject&gt;\\r\\n&lt;subj-group&gt;\\r\\n&lt;subject&gt;Focused Review Article&lt;/subject&gt;\\r\\n&lt;/subj-group&gt;\\r\\n&lt;/subj-group&gt;\\r\\n&lt;/article-categories&gt;\\r\\n&lt;title-group&gt;\\r\\n&lt;article-title&gt;Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs&lt;/article-title&gt;\\r\\n&lt;/title-group&gt;\\r\\n&lt;contrib-group&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot; corresp=\\&quot;yes\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Godman&lt;/surname&gt; &lt;given-names&gt;Brian&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff1\\&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff2\\&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;xref ref-type=\\&quot;author-notes\\&quot; rid=\\&quot;fn001\\&quot;&gt;&lt;sup&gt;&amp;#x0002A;&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/14310\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Malmstr&amp;#x000F6;m&lt;/surname&gt; &lt;given-names&gt;Rickard E.&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff3\\&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Diogene&lt;/surname&gt; &lt;given-names&gt;Eduardo&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff4\\&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Jayathissa&lt;/surname&gt; &lt;given-names&gt;Sisira&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff5\\&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;McTaggart&lt;/surname&gt; &lt;given-names&gt;Stuart&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff6\\&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/162461\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Cars&lt;/surname&gt; &lt;given-names&gt;Thomas&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff7\\&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff8\\&quot;&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/158496\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Alvarez-Madrazo&lt;/surname&gt; &lt;given-names&gt;Samantha&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff2\\&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Baumg&amp;#x000E4;rtel&lt;/surname&gt; &lt;given-names&gt;Christoph&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff9\\&quot;&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/76831\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Brzezinska&lt;/surname&gt; &lt;given-names&gt;Anna&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff10\\&quot;&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Bucsics&lt;/surname&gt; &lt;given-names&gt;Anna&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff11\\&quot;&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff12\\&quot;&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/66208\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Campbell&lt;/surname&gt; &lt;given-names&gt;Stephen&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff13\\&quot;&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Eriksson&lt;/surname&gt; &lt;given-names&gt;Irene&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff7\\&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Finlayson&lt;/surname&gt; &lt;given-names&gt;Alexander&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff14\\&quot;&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;F&amp;#x000FC;rst&lt;/surname&gt; &lt;given-names&gt;Jurij&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff15\\&quot;&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Garuoliene&lt;/surname&gt; &lt;given-names&gt;Kristina&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff16\\&quot;&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/76938\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Guti&amp;#x000E9;rrez-Ibarluzea&lt;/surname&gt; &lt;given-names&gt;I&amp;#x000F1;aki&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff17\\&quot;&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/17496\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Hviding&lt;/surname&gt; &lt;given-names&gt;Krystyna&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff18\\&quot;&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Herholz&lt;/surname&gt; &lt;given-names&gt;Harald&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff19\\&quot;&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Joppi&lt;/surname&gt; &lt;given-names&gt;Roberta&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff20\\&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/158660\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Kalaba&lt;/surname&gt; &lt;given-names&gt;Marija&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff21\\&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Laius&lt;/surname&gt; &lt;given-names&gt;Ott&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff22\\&quot;&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Malinowska&lt;/surname&gt; &lt;given-names&gt;Kamila&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff23\\&quot;&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff24\\&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Pedersen&lt;/surname&gt; &lt;given-names&gt;Hanne B.&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff25\\&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/139264\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Markovic-Pekovic&lt;/surname&gt; &lt;given-names&gt;Vanda&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff26\\&quot;&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff27\\&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Piessnegger&lt;/surname&gt; &lt;given-names&gt;Jutta&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff12\\&quot;&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Selke&lt;/surname&gt; &lt;given-names&gt;Gisbert&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff28\\&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Sermet&lt;/surname&gt; &lt;given-names&gt;Catherine&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff29\\&quot;&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/91670\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Spillane&lt;/surname&gt; &lt;given-names&gt;Susan&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff30\\&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Tomek&lt;/surname&gt; &lt;given-names&gt;Dominik&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff31\\&quot;&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Von&amp;#x0010D;ina&lt;/surname&gt; &lt;given-names&gt;Luka&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff32\\&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Vlahovi&amp;#x00107;-Pal&amp;#x0010D;evski&lt;/surname&gt; &lt;given-names&gt;Vera&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff33\\&quot;&gt;&lt;sup&gt;33&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Wale&lt;/surname&gt; &lt;given-names&gt;Janet&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff34\\&quot;&gt;&lt;sup&gt;34&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Wladysiuk&lt;/surname&gt; &lt;given-names&gt;Magdalena&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff35\\&quot;&gt;&lt;sup&gt;35&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;van Woerkom&lt;/surname&gt; &lt;given-names&gt;Menno&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff36\\&quot;&gt;&lt;sup&gt;36&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/76830\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Zara&lt;/surname&gt; &lt;given-names&gt;Corinne&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff37\\&quot;&gt;&lt;sup&gt;37&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/90535\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Gustafsson&lt;/surname&gt; &lt;given-names&gt;Lars L.&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff1\\&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/18251\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;/contrib-group&gt;\\r\\n&lt;aff id=\\&quot;aff1\\&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;institution&gt;Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge&lt;/institution&gt; &lt;country&gt;Stockholm, Sweden&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff2\\&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;institution&gt;Medicines Use and Health, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde&lt;/institution&gt; &lt;country&gt;Glasgow, UK&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff3\\&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;institution&gt;Clinical Pharmacology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna&lt;/institution&gt; &lt;country&gt;Stockholm, Sweden&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff4\\&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;institution&gt;Clinical Pharmacology Service, Vall d&amp;#x00027;Hebron University Hospital, Fundaci&amp;#x000F3; Institut Catal&amp;#x000E0; de Farmacologia, Autonomous University of Barcelona&lt;/institution&gt; &lt;country&gt;Barcelona, Spain&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff5\\&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;institution&gt;Department of Medicine, Hutt Valley DHB&lt;/institution&gt; &lt;country&gt;Lower Hutt, Wellington, New Zealand&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff6\\&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;institution&gt;Public Health and Intelligence Business Unit, NHS National Services Scotland&lt;/institution&gt; &lt;country&gt;Edinburgh, UK&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff7\\&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;institution&gt;Department of Healthcare Development, Public Healthcare Services Committee, Stockholm County Council&lt;/institution&gt; &lt;country&gt;Stockholm, Sweden&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff8\\&quot;&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;institution&gt;Department of Medical Sciences, Uppsala University&lt;/institution&gt; &lt;country&gt;Uppsala, Sweden&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff9\\&quot;&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;institution&gt;Austrian Medicines and Medical Devices Agency&lt;/institution&gt; &lt;country&gt;Wien, Austria&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff10\\&quot;&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;institution&gt;Agency for Health Technology Assessment&lt;/institution&gt; &lt;country&gt;Warsaw, Poland&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff11\\&quot;&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;institution&gt;Department of Finance, Faculty of Business, Economics and Statistics, University of Vienna&lt;/institution&gt; &lt;country&gt;Vienna, Austria&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff12\\&quot;&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;institution&gt;Hauptverband der &amp;#x000D6;sterreichischen Sozialversicherungstr&amp;#x000E4;ger&lt;/institution&gt; &lt;country&gt;Vienna, Austria&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff13\\&quot;&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;institution&gt;Centre for Primary Care, Institute of Population Health, University of Manchester&lt;/institution&gt; &lt;country&gt;Manchester, UK&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff14\\&quot;&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;institution&gt;Green Templeton College, University of Oxford&lt;/institution&gt; &lt;country&gt;Oxford, UK&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff15\\&quot;&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;institution&gt;Health Insurance Institute&lt;/institution&gt; &lt;country&gt;Ljubljana, Slovenia&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff16\\&quot;&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;institution&gt;Medicines Reimbursement Department, National Health Insurance Fund&lt;/institution&gt; &lt;country&gt;Vilnius, Lithuania&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff17\\&quot;&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;institution&gt;Basque Office for HTA, Ministry of Health and Consumer Affairs, Basque Government&lt;/institution&gt; &lt;country&gt;Basque Country, Spain&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff18\\&quot;&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;institution&gt;Norwegian Medicines Agency&lt;/institution&gt; &lt;country&gt;Oslo, Norway&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff19\\&quot;&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;institution&gt;Kassen&amp;#x000E4;rztliche Vereinigung Hessen&lt;/institution&gt; &lt;country&gt;Frankfurt am Main, Germany&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff20\\&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;institution&gt;Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona&lt;/institution&gt; &lt;country&gt;Verona, Italy&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff21\\&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;institution&gt;Department of Medicines and Pharmacoeconomics, Republic Institute for Health Insurance&lt;/institution&gt; &lt;country&gt;Belgrade, Serbia&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff22\\&quot;&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;institution&gt;State Agency of Medicines&lt;/institution&gt; &lt;country&gt;Tartu, Estonia&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff23\\&quot;&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;institution&gt;Department of Epidemiology and Health Promotion, Public Health School&lt;/institution&gt; &lt;country&gt;Warsaw, Poland&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff24\\&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;institution&gt;Drug Management Department, National Health Fund&lt;/institution&gt; &lt;country&gt;Warsaw, Poland&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff25\\&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;institution&gt;Division of Health Systems and Public Health, Health Technologies and Pharmaceuticals, WHO Regional Office for Europe&lt;/institution&gt; &lt;country&gt;Copenhagen, Denmark&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff26\\&quot;&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;institution&gt;Faculty of Medicine, University of Banja Luka&lt;/institution&gt; &lt;country&gt;Banja Luka, Bosnia and Herzegovina&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff27\\&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;institution&gt;Ministry of Health and Social Welfare&lt;/institution&gt; &lt;country&gt;Banja Luka, Bosnia and Herzegovina&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff28\\&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;institution&gt;Wissenschaftliches Institut der AOK (WidO)&lt;/institution&gt; &lt;country&gt;Berlin, Germany&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff29\\&quot;&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;institution&gt;IRDES&lt;/institution&gt; &lt;country&gt;Paris, France&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff30\\&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;institution&gt;Department of Pharmacology and Therapeutics, Trinity College Dublin&lt;/institution&gt; &lt;country&gt;Dublin, Ireland&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff31\\&quot;&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;institution&gt;Faculty of Pharmacy, Comenius University and Faculty of Medicine, Slovak Medical University&lt;/institution&gt; &lt;country&gt;Bratislava, Slovakia&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff32\\&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;institution&gt;Ministry of Health&lt;/institution&gt; &lt;country&gt;Zagreb, Croatia&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff33\\&quot;&gt;&lt;sup&gt;33&lt;/sup&gt;&lt;institution&gt;Unit for Clinical Pharmacology, University Hospital Rijeka&lt;/institution&gt; &lt;country&gt;Rijeka, Croatia&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff34\\&quot;&gt;&lt;sup&gt;34&lt;/sup&gt;&lt;institution&gt;Independent Consumer Advocate, VIC&lt;/institution&gt; &lt;country&gt;Melbourne, Australia&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff35\\&quot;&gt;&lt;sup&gt;35&lt;/sup&gt;&lt;institution&gt;HTA Consulting&lt;/institution&gt; &lt;country&gt;Cracow, Poland&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff36\\&quot;&gt;&lt;sup&gt;36&lt;/sup&gt;&lt;institution&gt;Dutch Institute for Rational Use of Medicine&lt;/institution&gt; &lt;country&gt;Utrecht, Netherlands&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff37\\&quot;&gt;&lt;sup&gt;37&lt;/sup&gt;&lt;institution&gt;Barcelona Health Region, Catalan Health Service&lt;/institution&gt; &lt;country&gt;Barcelona, Spain&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;author-notes&gt;\\r\\n&lt;fn fn-type=\\&quot;edited-by\\&quot;&gt;&lt;p&gt;Edited by: Dominique J. Dubois, Universit&amp;#x000E9; Libre de Bruxelles, Belgium&lt;/p&gt;&lt;/fn&gt;\\r\\n&lt;fn fn-type=\\&quot;edited-by\\&quot;&gt;&lt;p&gt;Reviewed by: Dominique J. Dubois, Universit&amp;#x000E9; Libre de Bruxelles, Belgium; Mark J. C. Nuijten, Ars Accessus Medica BV, Netherlands&lt;/p&gt;&lt;/fn&gt;\\r\\n&lt;fn fn-type=\\&quot;corresp\\&quot; id=\\&quot;fn001\\&quot;&gt;&lt;p&gt;&amp;#x0002A;Correspondence: &lt;email&gt;brian.godman&amp;#x00040;ki.se&lt;/email&gt;&lt;/p&gt;&lt;/fn&gt;\\r\\n&lt;fn fn-type=\\&quot;other\\&quot; id=\\&quot;fn002\\&quot;&gt;&lt;p&gt;This article was submitted to the journal Frontiers in Pharmacology.&lt;/p&gt;&lt;/fn&gt;\\r\\n&lt;/author-notes&gt;\\r\\n&lt;pub-date pub-type=\\&quot;epreprint\\&quot;&gt;\\r\\n&lt;day&gt;11&lt;/day&gt;\\r\\n&lt;month&gt;03&lt;/month&gt;\\r\\n&lt;year&gt;2014&lt;/year&gt;\\r\\n&lt;/pub-date&gt;\\r\\n&lt;pub-date pub-type=\\&quot;epub\\&quot;&gt;\\r\\n&lt;day&gt;10&lt;/day&gt;\\r\\n&lt;month&gt;06&lt;/month&gt;\\r\\n&lt;year&gt;2014&lt;/year&gt;\\r\\n&lt;/pub-date&gt;\\r\\n&lt;pub-date pub-type=\\&quot;collection\\&quot;&gt;\\r\\n&lt;year&gt;2014&lt;/year&gt;\\r\\n&lt;/pub-date&gt;\\r\\n&lt;volume&gt;5&lt;/volume&gt;\\r\\n&lt;elocation-id&gt;109&lt;/elocation-id&gt;\\r\\n&lt;history&gt;\\r\\n&lt;date date-type=\\&quot;received\\&quot;&gt;\\r\\n&lt;day&gt;19&lt;/day&gt;\\r\\n&lt;month&gt;02&lt;/month&gt;\\r\\n&lt;year&gt;2014&lt;/year&gt;\\r\\n&lt;/date&gt;\\r\\n&lt;date date-type=\\&quot;accepted\\&quot;&gt;\\r\\n&lt;day&gt;23&lt;/day&gt;\\r\\n&lt;month&gt;04&lt;/month&gt;\\r\\n&lt;year&gt;2014&lt;/year&gt;\\r\\n&lt;/date&gt;\\r\\n&lt;/history&gt;\\r\\n&lt;permissions&gt;\\r\\n&lt;copyright-statement&gt;Copyright &amp;#x000A9; 2014 Godman, Malmstr&amp;#x000F6;m, Diogene, Jayathissa, McTaggart, Cars, Alvarez-Madrazo, Baumg&amp;#x000E4;rtel, Brzezinska, Bucsics, Campbell, Eriksson, Finlayson, F&amp;#x000FC;rst, Garuoliene, Guti&amp;#x000E9;rrez-Ibarluzea, Hviding, Herholz, Joppi, Kalaba, Laius, Malinowska, Pedersen, Markovic-Pekovic, Piessnegger, Selke, Sermet, Spillane, Tomek, Von&amp;#x0010D;ina, Vlahovi&amp;#x00107;-Pal&amp;#x0010D;evski, Wale, Wladysiuk, van Woerkom, Zara and Gustafsson.&lt;/copyright-statement&gt;\\r\\n&lt;copyright-year&gt;2014&lt;/copyright-year&gt;\\r\\n&lt;license license-type=\\&quot;open-access\\&quot; xlink:href=\\&quot;http://creativecommons.org/licenses/by/3.0/\\&quot;&gt;&lt;p&gt;This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.&lt;/p&gt;\\r\\n&lt;/license&gt;\\r\\n&lt;/permissions&gt;\\r\\n&lt;abstract&gt;\\r\\n&lt;p&gt;&lt;bold&gt;Background&lt;/bold&gt;: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies showed dabigatran to be cost-effective but there are budget concerns given the prevalence of AF. These concerns resulted in extensive activities pre- to post-launch to manage its introduction.&lt;/p&gt;\\r\\n&lt;p&gt;&lt;bold&gt;Objective&lt;/bold&gt;: To (i) review authority activities across countries, (ii) use the findings to develop new models to better manage the entry of new drugs, and (iii) review the implications based on post-launch activities.&lt;/p&gt;\\r\\n&lt;p&gt;&lt;bold&gt;Methodology&lt;/bold&gt;: (i) Descriptive review and appraisal of activities regarding dabigatran, (ii) development of guidance for key stakeholder groups through an iterative process, (iii) refining guidance following post launch studies.&lt;/p&gt;\\r\\n&lt;p&gt;&lt;bold&gt;Results&lt;/bold&gt;: Plethora of activities to manage dabigatran including extensive pre-launch activities, risk sharing arrangements, prescribing restrictions and monitoring of prescribing post launch. Reimbursement has been denied in some countries due to concerns with its budget impact and/or excessive bleeding. Development of a new model and future guidance is proposed to better manage the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities. Post-launch activities include increasing use of patient registries to monitor the safety and effectiveness of new drugs in clinical practice.&lt;/p&gt;\\r\\n&lt;p&gt;&lt;bold&gt;Conclusion&lt;/bold&gt;: Models for introducing new drugs are essential to optimize their prescribing especially where concerns. Without such models, new drugs may be withdrawn prematurely and/or struggle for funding.&lt;/p&gt;\\r\\n&lt;/abstract&gt;\\r\\n&lt;kwd-group&gt;\\r\\n&lt;kwd&gt;critical drug evaluation&lt;/kwd&gt;\\r\\n&lt;kwd&gt;dabigatran&lt;/kwd&gt;\\r\\n&lt;kwd&gt;demand-side measures&lt;/kwd&gt;\\r\\n&lt;kwd&gt;managed introduction new medicines&lt;/kwd&gt;\\r\\n&lt;kwd&gt;registries&lt;/kwd&gt;\\r\\n&lt;/kwd-group&gt;\\r\\n&lt;counts&gt;\\r\\n&lt;fig-count count=\\&quot;2\\&quot;/&gt;\\r\\n&lt;table-count count=\\&quot;3\\&quot;/&gt;\\r\\n&lt;equation-count count=\\&quot;0\\&quot;/&gt;\\r\\n&lt;ref-count count=\\&quot;36\\&quot;/&gt;\\r\\n&lt;page-count count=\\&quot;10\\&quot;/&gt;\\r\\n&lt;word-count count=\\&quot;8144\\&quot;/&gt;\\r\\n&lt;/counts&gt;\\r\\n&lt;/article-meta&gt;\\r\\n&lt;/front&gt;\\r\\n&lt;body&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Background&lt;/title&gt;\\r\\n&lt;p&gt;Pharmaceutical expenditure is under increasing scrutiny, rising by more than 50% in real terms during the past decade among OECD countries (Godman et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B10\\&quot;&gt;2013&lt;/xref&gt;). This rate will continue unless addressed driven by well-known factors including changing demographics and the continual launch of new premium priced products (Garattini et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B9\\&quot;&gt;2008&lt;/xref&gt;; Godman et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B10\\&quot;&gt;2013&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). Continued pressure on resources is already resulting in some countries unable to fund new premium priced drugs (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). The number of countries is likely to increase if not addressed with new drugs, including new biological drugs, being launched at US&amp;#x00024;100,000&amp;#x02013;400,000 per patient per year or more (Kaiser, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B14\\&quot;&gt;2012&lt;/xref&gt;; Godman et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B10\\&quot;&gt;2013&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). This is in no one&amp;#x00027;s best interest especially if new medicines help improve patients&amp;#x00027; health either because they are more effective, have less side-effects, are easier to administer than current standards or a combination of these factors (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;; Spatz and McGee, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B25\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;&lt;bold&gt;Premium prices for new medicines are a concern&lt;/bold&gt; among health authorities struggling to maintain, and potentially incompatible with, the European ideals of comprehensive and equitable healthcare (Garattini et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B9\\&quot;&gt;2008&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). This can lead to conflicts between authorities and pharmaceutical companies with the latter keen to re-coup the considerable monies spent on Research and Development through encouraging the rapid reimbursement and uptake of new medicines. Uptake can be enhanced by companies spending up to one third of their income on marketing activities alongside lobbying activities (Civaner, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B2\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;boxed-text&gt;\\r\\n&lt;label&gt;KEY CONCEPT 1&lt;/label&gt;\\r\\n&lt;title&gt;Concerns with new medicines&lt;/title&gt;\\r\\n&lt;p&gt;Pharmaceutical expenditure is under increasing scrutiny among health authorities given ongoing pressures. Premium prices for new medicines are a concern especially if there are safety concerns with new medicines in clinical practice, which applied to new oral anticoagulants.&lt;/p&gt;\\r\\n&lt;/boxed-text&gt;\\r\\n&lt;p&gt;These conflicts between companies and authorities can be greater when there are safety concerns with new drugs, and they are subsequently prescribed in a wider population than studied in randomized clinical trials. Typically Phase III clinical trials are conducted under ideal and highly controlled conditions to seek high internal validity to maximize the chance of demonstrating clinical benefit (Fritz and Cleland, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B8\\&quot;&gt;2003&lt;/xref&gt;). However, this may lead to substantial differences from their subsequent use in clinical practice. Typically Phase III clinical trials do not include treatment preferences and/or multimodal treatment programs (Wells, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B29\\&quot;&gt;1999&lt;/xref&gt;; Fritz and Cleland, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B8\\&quot;&gt;2003&lt;/xref&gt;). Phase III clinical trials may also include a placebo group as a comparator in order to isolate the effects of a particular intervention (Fritz and Cleland, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B8\\&quot;&gt;2003&lt;/xref&gt;). These situations can lead to concerns with the generalizability of the findings when new drugs are being considered as an alternative to current treatments, especially once prescribed in patients with greater co-morbidities than those enrolled into Phase III clinical trials. They have also led to product withdrawals, which is in no one&amp;#x00027;s best interest. Examples include zimelidine, rofecoxib, and natalizumab (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;New oral anticoagulants (NOACs) illustrate some of these tensions as they show promise in the prevention of stroke in patients with atrial fibrillation (AF), offering an alternative to warfarin without the need for INR (International Normalized Ratio) monitoring (Pink et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B20\\&quot;&gt;2011&lt;/xref&gt;; Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). However, there are safety concerns especially in the elderly in addition to potential compliance problems (Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;; Marshall et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B18\\&quot;&gt;2013&lt;/xref&gt;; Xu et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B30a\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;AF is the most common clinically significant cardiac arrythmia with an estimated prevalence of 1&amp;#x02013;2% of the population (Marshall et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B18\\&quot;&gt;2013&lt;/xref&gt;). Current estimates suggest there are 4.5 million people in Europe with AF and 3.03 million in the US (Marshall et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B18\\&quot;&gt;2013&lt;/xref&gt;), with the prevalence of AF likely to double in the next 50 years with ageing populations (Pink et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B20\\&quot;&gt;2011&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;; Marshall et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B18\\&quot;&gt;2013&lt;/xref&gt;). New drugs are needed since patients with AF have a 5-fold increased risk of cardioembolic stroke compared with those in sinus rhythm (Pink et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B20\\&quot;&gt;2011&lt;/xref&gt;), with a cardioembolic stroke resulting in approximately 20% of patients dying in the acute phase and 60% developing severe disability (Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;). In addition, those patients with AF who survive are left more disabled by their stroke and are more likely to have a recurrence than those with other causes of stroke (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Anticoagulant therapy with Vitamin K antagonists (VKAs) can reduce by at least 60% the risk of stroke (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). However, there are concerns with warfarin due to the potential of bleeding, the need to tailor doses to the individual with too high a dose potentially causing serious complications and too low a dose losing protection, and the difficulties with maintaining some patients within International Normalized Ratios (Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Dabigatran received EU marketing authorization in August 2011 (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;) for the prevention of stroke and systemic embolism/clot formation in adult patients with non-valvular AF with one or more of the following risk factors:&lt;/p&gt;\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Previous stroke, transient ischemic attack or systemic embolism/clot formation.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Left ventricular ejection fraction &amp;#x0003C; 40%.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Symptomatic heart failure &amp;#x0003E; New York Heart Association (NYHA) class 2.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Age &amp;#x0003E; 75 years.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Age &amp;#x0003E; 65 years in combination with additional vascular risk, i.e., patients with diabetes mellitus, coronary artery disease or arterial hypertension.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;/list&gt;\\r\\n&lt;p&gt;Published studies showed a 9% reduction in the prevention of stroke or systemic embolism with dabigatran 110 mg twice daily and 34% for the 150 mg twice daily (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;; Marshall et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B18\\&quot;&gt;2013&lt;/xref&gt;). Overall mortality was also reduced by 12% for the highest dose of dabigatran, which reached statistical significance (Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). There was also an appreciable and consistent reduction in the risk of haemorrhagic stroke ranging from 69 to 74% depending on the dose of dabigatran. The 150 mg twice daily dose of dabigatran also resulted in a statistical significant reduction in ischemic stroke (24% risk reduction) (Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). Dabigatran could also potentially require no monitoring compared with warfarin (Godman et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B11\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). As a result, dabigatran has the potential to be an important new treatment, especially where regular monitoring with warfarin is problematic or where there are adverse events or other patient issues with warfarin.&lt;/p&gt;\\r\\n&lt;p&gt;These improvements, coupled with potential savings with dabigatran with the opportunity to reduce patient monitoring, resulted in incremental cost-effectiveness ratios (ICERs) of GB&amp;#x000A3;4831 (&amp;#x020AC;5560)/Quality adjusted life year (QALY) in patients under 80 vs. warfarin and GB&amp;#x000A3;7090 (&amp;#x020AC;8150) above 80 (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). A similar study in Sweden estimated the cost/QALY gained for dabigatran versus warfarin at &amp;#x020AC;7742, increasing to &amp;#x020AC;12,449 in patients who were well controlled with warfarin (Davidson et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B3\\&quot;&gt;2013&lt;/xref&gt;). Other authors have published higher ICERs, e.g., the National Institute for Health and Care Excellence (NICE) increased the base case ICER for dabigatran 150 mg twice to GB&amp;#x000A3;24,173&amp;#x02013;29,131 (&amp;#x020AC;27,790&amp;#x02013;33,490)/QALY with different assumptions (NICE, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B19\\&quot;&gt;2012&lt;/xref&gt;). However, NICE subsequently recommended dabigatran as an alternative to warfarin in patients who meet the criteria outlined in the marketing authorization approval (NICE, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B19\\&quot;&gt;2012&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;However, there have been concerns with the rapid introduction of &lt;bold&gt;dabigatran&lt;/bold&gt;. There were an appreciable number of serious adverse events within the first 12 weeks of dabigatran&amp;#x00027;s availability in the US (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). These were principally serious bleeding events or blood clots in the elderly (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). Dabigatran was also the most frequently identified medication involving direct safety-related reports to the FDA in 2011. These include haemorrhage, which was the most frequently reported side-effect (Carley et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B2a\\&quot;&gt;2014&lt;/xref&gt;). These concerns arose due to dabigatran&amp;#x00027;s low mean oral bioavailability, considerable variation in plasma drug concentrations, and dependence on renal elimination of the active metabolite (Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). Consequently, any accumulation of dabigatran in patients with reduced renal function will increase their risk of excessive bleeding, complicated by no effective reversal agent and no commercially available assay to measure blood levels of dabigatran (Legrand et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B15\\&quot;&gt;2011&lt;/xref&gt;; Harper et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B12\\&quot;&gt;2012&lt;/xref&gt;; Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;; Xu et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B30a\\&quot;&gt;2013&lt;/xref&gt;; Reilly et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B21\\&quot;&gt;2014&lt;/xref&gt;). These concerns are enhanced by potentially more elderly patients in clinical practice than seen in the Phase III clinical studies with the belief this would increase the risk of bleeding, which has now been demonstrated (Joppi et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B13\\&quot;&gt;2013&lt;/xref&gt;; Reilly et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B21\\&quot;&gt;2014&lt;/xref&gt;). There were also concerns with dabigantran&amp;#x00027;s budget impact (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). A number of health authorities and health insurance companies across Europe and other countries recognized these issues and initiated extensive pre- and peri-launch programmes to educate physicians and the public regarding the optimal use of dabigatran, especially in elderly patients with poor renal function (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;boxed-text&gt;\\r\\n&lt;label&gt;KEY CONCEPT 2&lt;/label&gt;\\r\\n&lt;title&gt;Dabigatran&lt;/title&gt;\\r\\n&lt;p&gt;The potential for inappropriate prescribing of dabigatran was a concern among health authorities across countries given the considerable variation in plasma concentration levels among the target elderly population, dependency on renal elimination of the active metabolite, no commercially available assay at launch and no effective reversal agent at launch. Consequently, the potential for serious bleeding and deaths if not administered appropriately, which happened in practice.&lt;/p&gt;\\r\\n&lt;/boxed-text&gt;\\r\\n&lt;p&gt;Consequently, we undertook a review of health authority and health insurance company activities across Europe pre- to post-launch of dabigatran for the prevention of stroke as an exemplar for developing future models to better manage the entry of new premium priced drugs. We subsequently used this knowledge to suggest future activities that all key stakeholder groups could undertake to optimize their use and reduce the likelihood of new drugs being removed from the market place due to safety concerns in a wider patient population. In addition, suggest activities to help control expenditure on new drugs where there are concerns with their budget impact. We have added to this advice based on post-launch studies with dabigatran in a number of countries.&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Methodology&lt;/title&gt;\\r\\n&lt;p&gt;Principally a descriptive review of initial national, regional or local health authority, health insurance company or physician association activities across Europe regarding dabigatran (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Demand-side initiatives were collated under four different activities named the 4 Es&amp;#x02014;Education, Engineering, Economics and Enforcement (Wettermark et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B30\\&quot;&gt;2009&lt;/xref&gt;). Illustrations of these include: (Wettermark et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B30\\&quot;&gt;2009&lt;/xref&gt;; Godman et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B10\\&quot;&gt;2013&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;):&lt;/p&gt;\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&lt;bold&gt;Educational activities&lt;/bold&gt;&amp;#x02014;Ranging from simple distribution of printed material to intensive strategies including academic detailing and monitoring of prescribing habits against agreed guidance usually by professional medical networks.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&lt;bold&gt;Engineering activities&lt;/bold&gt;&amp;#x02014;Organizational or managerial issues to influence change, e.g., quality and efficiency prescribing targets.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&lt;bold&gt;Economic interventions&lt;/bold&gt;&amp;#x02014;Financial incentives. These include financial incentives for physicians if they achieve agreed prescribing targets, devolution of drug budgets combined with regular monitoring of prescribing behavior and fines for prescribing costs above agreed limits as well as patient co-payments.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&lt;bold&gt;Enforcement&lt;/bold&gt;&amp;#x02014;Regulations by law such as compulsory International Non-proprietary Name (INN) prescribing, compulsory generic substitution, or prescribing restrictions such as restricting prescribing of new medicines to a defined patient sub-population.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;/list&gt;\\r\\n&lt;p&gt;This has been supplemented by post launch studies evaluating utilization patterns and patient populations in a range of countries and regions. These include Ireland, Italy, New Zealand, Scotland, Slovenia, Spain (Catalonia) and Sweden (Stockholm County Council). Typically, health authority databases and patient registries were used to access relevant patient and utilization data (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec sec-type=\\&quot;results\\&quot; id=\\&quot;s1\\&quot;&gt;\\r\\n&lt;title&gt;Results&lt;/title&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Health authority and health insurance company activities&lt;/title&gt;\\r\\n&lt;p&gt;Table &lt;xref ref-type=\\&quot;table\\&quot; rid=\\&quot;T1\\&quot;&gt;1&lt;/xref&gt; summarizes some of the health authority and health insurance company activities pre-, peri-, and post-launch up till the end of 2012 (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). Unless stated, the indications are those contained in the EMA marketing authorization (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;table-wrap position=\\&quot;float\\&quot; id=\\&quot;T1\\&quot;&gt;\\r\\n&lt;label&gt;Table 1&lt;/label&gt;\\r\\n&lt;caption&gt;&lt;p&gt;&lt;bold&gt;Summary of key activities across Europe to improve the quality and efficiency of prescribing of dabigatran (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;)&lt;/bold&gt;.&lt;/p&gt;&lt;/caption&gt;\\r\\n&lt;table frame=\\&quot;hsides\\&quot; rules=\\&quot;groups\\&quot;&gt;\\r\\n&lt;thead&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;&lt;bold&gt;Timing&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;&lt;bold&gt;Examples of activities among European countries and regions&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;/thead&gt;\\r\\n&lt;tbody&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Pre-launch (principally education)&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Stockholm County Council\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Systematic and long-term involvement of medical and scientific expertise in the development of guidelines and advice to patients and prescribers through the Regional Drugs and Therapeutic Committee (DTC) and clinical pharmacologists&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Extensive pre-launch activities with key messages broadcasted both to the public and to prescribers through websites of the DTC as well as the Swedish Medical Journal&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Appreciable number of pre-launch meetings and training sessions with all major physician groups around the key issues and concerns with dabigatran as well as its likely place in care&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Production of educational folders regarding dabigatran, slide kits, published articles, and data on the Janus website as well as published information for patients&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Forecasting the potential budget impact in 2011 and 2012 ahead of launch and monitoring this in practice&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Development of a laboratory method to monitor dabigatran in plasma with LC-MS/MS technology, and recommending sampling in the introductory phase to build a knowledge database. This to be followed by more situation-based sampling to improve patient safety in the future&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Peri-launch (principally education)&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;(A) Germany\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Physician Associations stressing when launched that the current knowledge regarding safety with dabigatran was insufficient to answer all questions, and physicians should be careful with prescribing particularly in the elderly&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;The reporting of deaths from excessive bleeding further endorsed these concerns. As a result, limited prescribing in practice in ambulatory care&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;\\r\\n&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td/&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;(B) Slovenia\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Reimbursed in conjunction with a complex price: volume agreement&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Post-launch (principally education and enforcement)&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;(A) Austria (education and enforcement)\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Publication of a guideline &amp;#x0201C;Anticoagulants and Platelet Inhibitors&amp;#x0201D; through a multi-stakeholder initiative including health insurers (Arznei Vernunft, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B1b\\&quot;&gt;2014&lt;/xref&gt;)&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Ex ex-ante approval by the head physician of the patient&amp;#x00027;s social health insurance fund before reimbursement of dabigatran; otherwise 100% co-payment (mirroring other situations)&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Renal function has to be assessed and recorded prior to initiation of therapy with dabigatran through determining Creatinine-Clearance (CrCl) levels to exclude patients with severe renal dysfunction (&amp;#x0003D;CrCl &amp;#x0003C;30 ml/min). In addition during treatment, renal function has to be monitored where a decline is envisaged, e.g., patients with hypovolaemia, dehydration and the use of specific additional medication, and renal function has to be assessed at least once a year in patients aged 75 or older, and/or in patients with compromized renal function&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td/&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;(B) Slovenia\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Education of all involved specialists and primary physicians on key safety aspects/ adverse events with dabigatran&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Prescribing restrictions (Enforcement):\\r\\n&lt;list list-type=\\&quot;simple\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&amp;#x02013; Only reimbursed if initiated by an internist or neurologist and prescribed according to agreed indications, e.g., only reimbursed in patients already on warfarin if they are unstable with TTR &amp;#x0003C; 65&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&amp;#x02013; Patients have to be followed in a tertiary or secondary anticoagulation centre. Patients can be followed in primary care but only if authorized by tertiary or secondary center&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&amp;#x02013; Every patient has to be registered in a database and followed by the IT anticoagulation programme&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&amp;#x02013; Anticoagulation centers have to report once yearly to the tertiary center regarding the number of patients experiencing minor and major bleeding, thromboembolic events, as well as any deaths from bleeding or thromboembolism with dabigatran&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;&amp;#x02013; No longer a need to report separately to the National Health Insurance (ZZZS)&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;/list&gt;&lt;/p&gt;\\r\\n&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;/tbody&gt;\\r\\n&lt;/table&gt;\\r\\n&lt;/table-wrap&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Proposed model and associated activities&lt;/title&gt;\\r\\n&lt;p&gt;Figure &lt;xref ref-type=\\&quot;fig\\&quot; rid=\\&quot;F1\\&quot;&gt;1&lt;/xref&gt; outlines the suggested new model to &lt;bold&gt;better manage the utilization of new medicines&lt;/bold&gt; in the future. This is based on extensive knowledge and experience including pre- to post-launch activities with dabigatran shared across healthcare institutions. This builds on the identified three pillars of pre, peri-, and post-launch activities (Godman et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B11\\&quot;&gt;2012&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;fig id=\\&quot;F1\\&quot; position=\\&quot;float\\&quot;&gt;\\r\\n&lt;label&gt;Figure 1&lt;/label&gt;\\r\\n&lt;caption&gt;&lt;p&gt;&lt;bold&gt;Proposed model for optimizing the managed entry of new drugs across Europe incorporating national and regional stakeholder groups where pertinent building on the example of dabigatran (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;)&lt;/bold&gt;.&lt;/p&gt;&lt;/caption&gt;\\r\\n&lt;graphic xlink:href=\\&quot;fphar-05-00109-g0001.tif\\&quot;/&gt;\\r\\n&lt;/fig&gt;\\r\\n&lt;boxed-text&gt;\\r\\n&lt;label&gt;KEY CONCEPT 3&lt;/label&gt;\\r\\n&lt;title&gt;Better manage the utilization of new medicines&lt;/title&gt;\\r\\n&lt;p&gt;Potential models can be developed to optimise the use of new medicines. This starts pre-launch with horizon scanning, budgeting and physician education, through peri-launch with critical evaluation of the potential role and value of new medicines, and carrying onto post launch. Post launch activities include patient registries to monitor the prescribing of new medicines including potential safety issues and outcomes, as well as the prescribing against agreed guidance.&lt;/p&gt;\\r\\n&lt;/boxed-text&gt;\\r\\n&lt;p&gt;The proposed model starts with horizon scanning activities pre-launch. Post launch activities include monitoring current prescribing, benchmarking and entering patient details on registries.&lt;/p&gt;\\r\\n&lt;p&gt;Key issues for health authorities to consider when appraising possible risk sharing arrangements or managed entry agreements have already been summarized (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). The same applies to key issues and considerations before implementing patient registries (Figure &lt;xref ref-type=\\&quot;fig\\&quot; rid=\\&quot;F1\\&quot;&gt;1&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Overall, there are a number of activities that each key stakeholder group should consider pre-, peri-, and post-launch to better manage the entry of new drugs. This is especially important where there are potential safety and/or resource issues with new premium priced drugs (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Post launch studies&lt;/title&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Italy&lt;/title&gt;\\r\\n&lt;p&gt;A recent study using a population-oriented database for medicine use aimed to describe clinical features and pharmacological treatments of a population-based cohort of Italian patients discharged from the hospital with a diagnosis of non-valvular AF. Subsequently, to compare these patients with those included in the RE-LY, ROCKET AF, and ARISTOTLE studies for dabigatran, rivaroxaban, and apixaban respectively (Joppi et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B13\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Of the 2,862,264 subjects considered for the study, 13,360 patients (0.47%) were discharged from hospitals with a diagnosis of non-valvular AF. Their mean age was 76.3 (SD 10.7), 49.8% were men and 64.6% were &amp;#x02265;75 years of age. This compares with a mean age of 71.5 &amp;#x000B1; 8.7 in the Re-LY study, a proportion of women &amp;#x0003C; 40%, and approximately 40% &amp;#x02265;75 years of age.&lt;/p&gt;\\r\\n&lt;p&gt;Fifty percent of patients were treated with warfarin and 44.1% with antiplatelet agents. The proportion of patients on antiplatelet therapy increased with age, up to a rate of 54.3% in subjects &amp;#x02265;85 years. 92.9% of the studied cohort were on polypharmacy (mean 8 drugs/patient). Approximately 20% of the entire cohort was treated with amiodarone, a drug potentially interfering with NOACs, and 3.6% from a subgroup analysis had renal failure, which is an exclusion criterion in trials on NOACs (Joppi et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B13\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;The results of this survey demonstrate once more that considerable efforts should be made by pharmaceutical companies and others to include more women and elderly people in randomized clinical trials. Furthermore, while suggesting a role for NOACs in satisfying patients&amp;#x00027; needs, there is still unmet need. Further phase IV studies are also required to confirm the benefits and clarify the safety profile of novel oral anticoagulants in routine clinical practice (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;New zealand&lt;/title&gt;\\r\\n&lt;p&gt;A recent study conducted among patients recruited from the medical services at Lower Hutt Hospital and two large general practices in New Zealand also showed less predominance of men than the RE-LY study (42 vs. 63%), an older cohort (73 vs. 71 years) and greater morbidity (Thorne et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B27\\&quot;&gt;2014&lt;/xref&gt;). This is in keeping with differences between patients seen in RCTs compared with those in real life.&lt;/p&gt;\\r\\n&lt;p&gt;The authors did not observe inappropriate prescribing of dabigatran according to patients&amp;#x00027; renal function. They believed this may reflect extensive local educational initiatives by the Best Practice Advisory Centre (BPAC) as well as initiatives by local prescribers pre- and peri-launch. This suggests that prescribers can be educated to operate within accepted guidelines, providing guidance for the future (Thorne et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B27\\&quot;&gt;2014&lt;/xref&gt;). There were a high number of adverse events reported to New Zealand Centre for Adverse Drug Reaction Monitoring after the launch of dabigatran. However, increased publicity on adverse events and increasing knowledge about dabigatran among prescribers in New Zealand, especially regarding renal function, led to a reduction in number of adverse reactions reported to the New Zealand Centre for Adverse Drug Reaction Monitoring in recent months (Thorne et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B27\\&quot;&gt;2014&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Ireland&lt;/title&gt;\\r\\n&lt;p&gt;Patterns of dabigatran prescribing were investigated in a national-level prescription claims database. Dispensing records from January-October 2013 inclusive were studied and patients with a dabigatran supply duration of greater than 35 days were assumed to be non-valvular atrial fibrillation patients. 5887 (85%) patients were identified as having received dabigatran, 5012 (83%) of whom received the drug for &amp;#x0003E;35 days. 62% of patients who received dabigatran for &amp;#x0003E;35 days were 75 years or older and 37% were 80 years or older. 56% of patients were male. A high proportion of patients were found to be concurrently receiving drugs which may increase the bleeding risk associated with dabigatran use: 36% of patients receiving dabigatran for &amp;#x0003E;35 days were found to have also received at least one &amp;#x0201C;caution&amp;#x0201D; drug (defined as per SmPC) when dispensed dabigatran.&lt;/p&gt;\\r\\n&lt;p&gt;This analysis followed publications from various authorities in Ireland as there were concerns with the prescribing of dabigatran in clinical practice (National Medicines Information Centre, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B18a\\&quot;&gt;2012&lt;/xref&gt;; Barry, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B1a\\&quot;&gt;2013&lt;/xref&gt;; Irish Medicines Board, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B12a\\&quot;&gt;2013&lt;/xref&gt;). Following the analysis, a letter has now been sent by the authorities to all physicians in Ireland reminding them of the appropriate prescribing of NOACs based on the findings.&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Scotland&lt;/title&gt;\\r\\n&lt;p&gt;In May 2008, the Scottish Medicines Consortium (SMC) accepted dabigatran for use in the prevention of venous thromboembolic events following total hip or total knee replacement surgery (SMC, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B23\\&quot;&gt;2008&lt;/xref&gt;). However, it was not until late 2011 with acceptance of its use by SMC for the prevention of stroke and systemic embolism in adult patients with non-valvular AF (SMC, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B24\\&quot;&gt;2011&lt;/xref&gt;) that greater use was seen in ambulatory care (Figure &lt;xref ref-type=\\&quot;fig\\&quot; rid=\\&quot;F2\\&quot;&gt;2&lt;/xref&gt;) (Scott and McTaggart, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B22\\&quot;&gt;2013&lt;/xref&gt;). Analysis of the number of patients dispensed a prescription for dabigatran showed a faster and much greater uptake in rural compared with urban areas (Figure &lt;xref ref-type=\\&quot;fig\\&quot; rid=\\&quot;F2\\&quot;&gt;2&lt;/xref&gt;). The reasons for this are currently being explored, but might reflect differences in access to anticoagulant monitoring services and the perceived advantage of dabigatran in this respect (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). The rates in Figure &lt;xref ref-type=\\&quot;fig\\&quot; rid=\\&quot;F2\\&quot;&gt;2&lt;/xref&gt; were standardized against the population aged 50 years or over to take account of different demographics and because this is the age group in which AF is most common.&lt;/p&gt;\\r\\n&lt;fig id=\\&quot;F2\\&quot; position=\\&quot;float\\&quot;&gt;\\r\\n&lt;label&gt;Figure 2&lt;/label&gt;\\r\\n&lt;caption&gt;&lt;p&gt;&lt;bold&gt;Patients per 100,000 population aged 50 years and over receiving a prescription for dabigatran by month and type of location (Scott and McTaggart, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B22\\&quot;&gt;2013&lt;/xref&gt;)&lt;/bold&gt;.&lt;/p&gt;&lt;/caption&gt;\\r\\n&lt;graphic xlink:href=\\&quot;fphar-05-00109-g0002.tif\\&quot;/&gt;\\r\\n&lt;/fig&gt;\\r\\n&lt;p&gt;The overall use of dabigatran, as well as rivaroxaban, still remains modest compared with warfarin in Scotland. This may reflect extensive educational input pre- to post-launch highlighting where pertinent that warfarin should remain first line treatment especially with no known antidote for dabigatran (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;In contrast to the findings from the other countries described, the population treated with dabigatran in Scotland appears much closer in age and ratio of men to women to those patients included in the RE-LY trial:&lt;/p&gt;\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Number of patients: 642 (&lt;italic&gt;M&lt;/italic&gt; &amp;#x0003D; 391, &lt;italic&gt;F&lt;/italic&gt; &amp;#x0003D; 251).&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Median age: 72 years (&lt;italic&gt;M&lt;/italic&gt; &amp;#x0003D; 69, &lt;italic&gt;F&lt;/italic&gt; &amp;#x0003D; 75 years).&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Mean age: 70.83 (&lt;italic&gt;M&lt;/italic&gt; &amp;#x0003D; 68.92 years, &lt;italic&gt;SD&lt;/italic&gt; &amp;#x0003D; 12.4; &lt;italic&gt;F&lt;/italic&gt; &amp;#x0003D; 73.81 years, &lt;italic&gt;SD&lt;/italic&gt; &amp;#x0003D; 11.599).&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;/list&gt;\\r\\n&lt;p&gt;This may again reflect a greater use among a broader population in rural areas; however, this remains to be proven. We acknowledge though that we have not broken the ages of patients down by indication. However as seen in Figure &lt;xref ref-type=\\&quot;fig\\&quot; rid=\\&quot;F2\\&quot;&gt;2&lt;/xref&gt;, there was limited use of dabigatran in ambulatory care prior to SMC approval for its use in patients with AF.&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Slovenia&lt;/title&gt;\\r\\n&lt;p&gt;Recent analysis of the utilization of dabigatran and warfarin by the Health Insurance Institute of reimbursed prescriptions (Table &lt;xref ref-type=\\&quot;table\\&quot; rid=\\&quot;T2\\&quot;&gt;2&lt;/xref&gt;) would suggest that the prescribing of dabigatran is being restricted in accordance to the regulations (Table &lt;xref ref-type=\\&quot;table\\&quot; rid=\\&quot;T1\\&quot;&gt;1&lt;/xref&gt;). However, the situation is being monitored in secondary and tertiary anticoagulation centers.&lt;/p&gt;\\r\\n&lt;table-wrap position=\\&quot;float\\&quot; id=\\&quot;T2\\&quot;&gt;\\r\\n&lt;label&gt;Table 2&lt;/label&gt;\\r\\n&lt;caption&gt;&lt;p&gt;&lt;bold&gt;Utilization of reimbursed anti-coagulants in Slovenia (DDDs/One Thousand Inhabitants/Day &amp;#x02013; DID)&lt;/bold&gt;.&lt;/p&gt;&lt;/caption&gt;\\r\\n&lt;table frame=\\&quot;hsides\\&quot; rules=\\&quot;groups\\&quot;&gt;\\r\\n&lt;thead&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;th/&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;2009&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;2010&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;2011&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;2012&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;2013&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;/thead&gt;\\r\\n&lt;tbody&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Dabigatran&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;0.012&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;0.030&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;0.058&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;0.217&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;1.134&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Warfarin&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;8.553&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;8.477&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;8.843&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;9.329&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;9.202&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;/tbody&gt;\\r\\n&lt;/table&gt;\\r\\n&lt;/table-wrap&gt;\\r\\n&lt;p&gt;There was some utilization of dabigatran prior to reimbursement in August 2012. This may represent use in patients undergoing orthopaedic surgery.&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Spain (catalonia)&lt;/title&gt;\\r\\n&lt;p&gt;A number of activities were undertaken in Catalonia particularly post launch to help optimize the prescribing of dabigatran (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). A recent follow-up of patients with AF prescribed dabigatran in Catalonia showed the following (Troncoso and Diog&amp;#x000E8;ne, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B28\\&quot;&gt;2014&lt;/xref&gt;):&lt;/p&gt;\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Patients were older than in the RE-LY study: median age: 77 vs. 71 years and proportion of men lower [52.4 vs. 64.3%] and renal function was lower [creatinine clearance: 25.3% &amp;#x0003C; 50 mL/min vs. 19.4%].&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;One-third of the patients followed up were &amp;#x0003E;80 years old; of the 631 patients, 103 were not receiving the recommended dose of dabigatran.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;There were 298 (17.2%) patients with previous ischemic heart disease and 36 (2.1%) patients with severe renal impairment for whom dabigatran should be contraindicated.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Renal function was not recorded in electronic records during the previous year for 517 patients (30%), and a large number of patients had been prescribed dosages of dabigatran that were not recommended.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;Fifteen patients on dabigatran and oral verapamil were prescribed dosages that are not recommended.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;/list&gt;\\r\\n&lt;p&gt;These findings suggest that additional activities are still needed in Catalonia to improve the prescribing of dabigatran. These include information to prescribers, electronic tools to support physicians&amp;#x00027; decision-making as well as greater monitoring of the prescribing of NOACs (Troncoso and Diog&amp;#x000E8;ne, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B28\\&quot;&gt;2014&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Sweden (stockholm county council)&lt;/title&gt;\\r\\n&lt;p&gt;Analysis of 2363 patients receiving at least one prescription for dabigatran in Stockholm County Council between 2012 and 2013 with a registered diagnosis of non-valvular AF five years or less before the first prescription of dabigatran, and excluding patients where the speciality code for patients&amp;#x00027; first prescription was surgery/orthopaedics, showed similar ages to patients enrolled into the RE-LY study (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;) (Table &lt;xref ref-type=\\&quot;table\\&quot; rid=\\&quot;T3\\&quot;&gt;3&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;table-wrap position=\\&quot;float\\&quot; id=\\&quot;T3\\&quot;&gt;\\r\\n&lt;label&gt;Table 3&lt;/label&gt;\\r\\n&lt;caption&gt;&lt;p&gt;&lt;bold&gt;Patient ages prescribed at least one prescription for dabigatran 2012&amp;#x02013;2013&lt;/bold&gt;.&lt;/p&gt;&lt;/caption&gt;\\r\\n&lt;table frame=\\&quot;hsides\\&quot; rules=\\&quot;groups\\&quot;&gt;\\r\\n&lt;thead&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;th/&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;&lt;italic&gt;n&lt;/italic&gt; &amp;#x0003D;&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;Mean age (years)&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;Min age (years)&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;Max (years)&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;th valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;&lt;bold&gt;&lt;italic&gt;SD&lt;/italic&gt;&lt;/bold&gt;&lt;/th&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;/thead&gt;\\r\\n&lt;tbody&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Female&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;1002 (42.4%)&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;73.1&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;34&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;96&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;9.2&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Male&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;1361 (57.6%)&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;68&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;24&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;95&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;10.7&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;tr&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;left\\&quot;&gt;Total&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;2363&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;70.2&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;24&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;96&lt;/td&gt;\\r\\n&lt;td valign=\\&quot;top\\&quot; align=\\&quot;center\\&quot;&gt;10.4&lt;/td&gt;\\r\\n&lt;/tr&gt;\\r\\n&lt;/tbody&gt;\\r\\n&lt;/table&gt;\\r\\n&lt;table-wrap-foot&gt;\\r\\n&lt;p&gt;&lt;italic&gt;NB, Age calculations were based on the patients&amp;#x00027; age at the first prescription&lt;/italic&gt;.&lt;/p&gt;\\r\\n&lt;/table-wrap-foot&gt;\\r\\n&lt;/table-wrap&gt;\\r\\n&lt;p&gt;This compares with a recent analysis of 43,353 individuals with non-valvular AF in the Stockholm County Council database between 2006 and2010. The analysis showed 54% of patients were 75 years or older, 39% were 80 years or older, and 44% of patients were women (Forslund et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B7\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;The strength of dabigatran prescribed varied by age, with lower doses prescribed for more elderly patients:&lt;/p&gt;\\r\\n&lt;list list-type=\\&quot;bullet\\&quot;&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;66.9% dispensed 150 mg with a mean age of 66.4.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;30.1% dispensed 110 mg with a mean age of 77.5 years.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;list-item&gt;&lt;p&gt;3.0% dispensed 75 mg with a mean age of 80.3 years.&lt;/p&gt;&lt;/list-item&gt;\\r\\n&lt;/list&gt;\\r\\n&lt;p&gt;Further analysis is planned to see if the lower doses prescribed in patients with a mean ages of 77.5 and 80.3 years correlates with poorer renal function through analyzing their electronic health records.&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Summary of the findings&lt;/title&gt;\\r\\n&lt;p&gt;The findings from these post launch studies demonstrate that the patient population in clinical practice can be very different to those enrolled in Phase III trials, making extraction from the trial data sometimes difficult. They also demonstrate the need for educating physicians pre-launch if there are safety concerns and contra-indications with new products to reduce adverse drug reactions post launch.&lt;/p&gt;\\r\\n&lt;p&gt;The studies also show the potential to pool the findings from &lt;bold&gt;patient registries&lt;/bold&gt; post launch to gain more rapid insights.&lt;/p&gt;\\r\\n&lt;boxed-text&gt;\\r\\n&lt;label&gt;KEY CONCEPT 4&lt;/label&gt;\\r\\n&lt;title&gt;Patient registries&lt;/title&gt;\\r\\n&lt;p&gt;Patient registries as well as the active monitoring of prescribing of dabigatran were undertaken in a number of countries. These showed the age of the patients in clinical practice was often higher than those seen in the Phase III clinical trials and there was a higher proportion of women. Pre- and peri-launch educational activities among health authorities helped reduce potential adverse drug reactions; however, additional measures are needed in some countries to address dosing concerns and contra-indications to optimise the future prescribing of dabigatran.&lt;/p&gt;\\r\\n&lt;/boxed-text&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec sec-type=\\&quot;discussion\\&quot; id=\\&quot;s2\\&quot;&gt;\\r\\n&lt;title&gt;Discussion&lt;/title&gt;\\r\\n&lt;p&gt;Dabigatran and the other new oral anti-coagulants (NOACs) are the result of a long search for an alternative to warfarin to prevent strokes in patients with AF. However, the weighing of the advantages and disadvantages associated with dabigatran, especially in the elderly with poor renal function, needs to be judged carefully and handled appropriately alongside the additional acquisition costs of dabigatran (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;; Xu et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B30a\\&quot;&gt;2013&lt;/xref&gt;; Carley et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B2a\\&quot;&gt;2014&lt;/xref&gt;). This was especially the case in this situation with no widely available assay pre-launch, exacerbated by concerns from the Company regarding the potential for undermining their message about no monitoring (Reilly et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B21\\&quot;&gt;2014&lt;/xref&gt;; Thomas, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B26\\&quot;&gt;2014&lt;/xref&gt;). These challenges resulted in an extensive range of activities among health authorities, health insurance companies and physician associations across Europe pre- to post-launch to enhance its appropriate use based on factors including age and kidney function (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). Similar findings were seen in New Zealand, Ontario, Canada and Wisconsin, USA (Xu et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B30a\\&quot;&gt;2013&lt;/xref&gt;; Carley et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B2a\\&quot;&gt;2014&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Cases of major bleeding and deaths that were seen with dabigatran soon after its launch, justify the need for the suggested model (Figure &lt;xref ref-type=\\&quot;fig\\&quot; rid=\\&quot;F1\\&quot;&gt;1&lt;/xref&gt;) to improve the managed entry of new drugs (Legrand et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B15\\&quot;&gt;2011&lt;/xref&gt;; Harper et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B12\\&quot;&gt;2012&lt;/xref&gt;; Mannuci et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B17\\&quot;&gt;2012&lt;/xref&gt;; Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). The EMA also reported on 6 November 2011 that there had already been 256 spontaneous reports of serious bleeding resulting in deaths in the EudraVigilance database (EMA, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B4\\&quot;&gt;2011&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Extensive activities among the authorities included educational activities pre-launch in Stockholm County Council, Sweden, as well as post-launch activities among regions and localities in Germany, Spain, Sweden, and the UK (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). There were also prescribing restrictions in some countries alongside the development of shared care protocols between sectors. It is suggested these activities helped reduce subsequent bleeding among patients in practice, especially among those with poor renal function and, as a result, help preserve the availability of dabigatran. However, it is difficult to substantiate this without definite research. Having said this, some of the findings post launch suggests that such activities helped enhance the appropriate use of dabigatran (Carley et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B2a\\&quot;&gt;2014&lt;/xref&gt;; Thorne et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B27\\&quot;&gt;2014&lt;/xref&gt;). Further efforts are still needed in some countries to improve the prescribing of dabigatran, e.g., Spain (Catalonia) (Troncoso and Diog&amp;#x000E8;ne, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B28\\&quot;&gt;2014&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;There have also been issues with the additional costs of dabigatran vs. warfarin at GB&amp;#x000A3;919.80 (&amp;#x020AC;1060) per patient per year (UK) given the growing prevalence of AF with currently over 4.5 to 6 million patients across Europe and rising (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). However, there is less of a budget differential in Sweden (Davidson et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B3\\&quot;&gt;2013&lt;/xref&gt;). These combined issues led to (i) prescribing restrictions in some countries alongside prior authorization schemes, e.g., Austria, Belgium, Finland, Slovakia, and Slovenia, (ii) delays with reimbursement in others including Croatia (recently reimbursed as second line to warfarin with a 50% co-payment), the Netherlands, Norway and Portugal (150 mg); and (iii) price: volume and other agreements (risk sharing) to lower the cost of dabigatran, e.g., Ireland, the Netherlands and Slovenia [2]. These concerns also resulted in dabigatran not being reimbursed in some countries, e.g., Estonia, Lithuania, Poland, the Republic of Serbia and the Republic of Srpska (constitutive entity in Bosnia and Herzegovina). Prescribing restrictions and risk sharing arrangements are no doubt preferred by manufacturers versus not having their drugs reimbursed.&lt;/p&gt;\\r\\n&lt;p&gt;The weighing of the benefits and concerns with dabigatran make it increasingly important for European countries and regions to develop and refine models to further improve the managed entry of new premium priced drugs, even if they do not have a tradition of Health Technology Assessment (HTA). As mentioned, the alternative could be reduced resources to fund new drugs in the future, especially with a growing elderly population, which is already happening (Malmstr&amp;#x000F6;m et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B16\\&quot;&gt;2013&lt;/xref&gt;). Such models may also reduce the possibility of new drugs such as dabigatran being withdrawn from the market due to a greater level of side-effects in a wider co-morbid population. None of these alternative scenarios are in the best interests of any key stakeholder group.&lt;/p&gt;\\r\\n&lt;p&gt;We hope we have demonstrated why it is imperative that health authorities and health insurance agencies continue to develop and refine new models to better manage the entry of new drugs. We hope we have also provided direction to all key stakeholder groups to further stimulate the debate about potential activities in this critically important area. This especially as the constant introduction of new premium priced drugs is seen as the greatest challenge to the continued provision of equitable and comprehensive healthcare in Europe (Garattini et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B9\\&quot;&gt;2008&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec sec-type=\\&quot;conclusion\\&quot; id=\\&quot;s3\\&quot;&gt;\\r\\n&lt;title&gt;Conclusion&lt;/title&gt;\\r\\n&lt;p&gt;There were multiple activities pre- to post-launch among authorities across Europe and other countries to improve the prescribing of dabigatran, especially in elderly patients where there are concerns with their renal function. In addition, address potential concerns with the budget impact of dabigatran through for instance price: volume agreements and prescribing restrictions.&lt;/p&gt;\\r\\n&lt;p&gt;We believe and recommend, based on the experiences with dabigatran and other new premium priced drugs, that it is essential that health authorities develop new models to better manage the entry of new drugs in the future (Figure &lt;xref ref-type=\\&quot;fig\\&quot; rid=\\&quot;F1\\&quot;&gt;1&lt;/xref&gt;). This is becoming critical given the considerable number of new biological drugs in development (Evaluate Pharma, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B5\\&quot;&gt;2012&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Critical activities for health authorities pre-launch include horizon scanning and budget planning activities. This includes identifying products likely to lose their patent within the next one to two years. This is because the price of generics can be as low as 2&amp;#x02013;10% of pre-patent loss prices, with activities to enhance the prescribing of low cost generics realizing considerable savings (Godman et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B10\\&quot;&gt;2013&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Educational materials and clinical guidance also need to be developed pre-launch with the help of physicians and patient groups. Key peri-launch activities include developing prescribing indicators for new treatments as well as the critical appraisal of any proposed risk sharing arrangements. Increasingly discounts are preferred for new drugs rather than complicated arrangements including outcome schemes in view of the complexities involved (Adamski et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B1\\&quot;&gt;2010&lt;/xref&gt;; Ferrario and Kanavos, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B6\\&quot;&gt;2013&lt;/xref&gt;). Essential post launch activities include monitoring of prescribing against agreed guidance with further educational input if needed. Activities also include increasingly entering patients into registries to monitor the effectiveness and safety of new drugs in wider patient populations.&lt;/p&gt;\\r\\n&lt;p&gt;Without such models, authorities may well struggle to maintain the European ideals of equitable and comprehensive healthcare as well as ensuring funding for new &amp;#x0201C;valued&amp;#x0201D; treatments in target populations. Consequently, the development of new models to better manage the entry of new drugs should be in the interest of all key stakeholder groups.&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Author contributions&lt;/title&gt;\\r\\n&lt;p&gt;Brian Godman, Rickard E. Malmstr&amp;#x000F6;m, Eduardo Diogene, Alexander Finlayson, Magdalena Wladysiuk, Hanne B. Pedersen, Lars L. Gustafsson conceived of the study design, produced the first draft and critiqued subsequent drafts. Christoph Baumg&amp;#x000E4;rtel also commented on the differences in design for controlled studies vs. clinical practice. Sisira Jayathissa provided data on New Zealand and critiqued subsequent drafts. Stuart McTaggart and Samantha Alvarez-Madrazo provided data on Scotland and critiqued subsequent drafts. Thomas Cars and Irene Eriksson provided data on Sweden and critiqued successive drafts. Anna Brzezinska and Kamila Malinowska provided input on Poland and critiqued successive drafts. Anna Bucsics and Jutta Piessnegger provided input on Austria and critiqued successive drafts. Stephen Campbell contributed to successive drafts including issues of patient registries and quality indicators. Jurij F&amp;#x000FC;rst provided data on Slovenia and critiqued successive drafts. Kristina Garuoliene provided input on Lithuania and critiqued successive drafts. I&amp;#x000F1;aki Guti&amp;#x000E9;rrez-Ibarluzea provided input regarding per-launch and post-launch activities including issues such as managed entry agreements and registries. Krystyna Hviding provided input regarding Norway and critiqued successive drafts. Harald Herholz and Gisbert Selke provided input on Germany and critiqued successive drafts. Roberta Joppi provided data on Italy and critiqued successive drafts. Marija Kalaba provided input on Serbia and critiqued successive drafts. Ott Laius provided input on Estonia and critiqued successive draft. Vanda Markovic-Pekovic provided input on the Republic of Srpska and critiqued successive drafts. Catherine Sermet provided input on France and critiqued successive drafts. Susan Spillane provided data on Ireland as well as appropriate references. Dominik Tomek provided input on Slovakia and critiqued successive draft. Luka Von&amp;#x0010D;ina and Vera Vlahovi&amp;#x00107;-Pal&amp;#x0010D;evski provided input on Croatia and critiqued successive drafts. Janet Wale critiqued successive drafts based on her experiences with patients/patient organizations. Menno van Woerkom provided input regarding the Netherlands and critiqued successive drafts. Corinne Zara provided input regarding Spain and critiqued successive drafts.&lt;/p&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Conflict of interest statement&lt;/title&gt;\\r\\n&lt;p&gt;A number of the authors are employed by health authorities or health insurance companies or are advisers to them concerning potential funding of new medicines. Otherwise the authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.&lt;/p&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;/sec&gt;\\r\\n&lt;/body&gt;\\r\\n&lt;back&gt;\\r\\n&lt;ack&gt;\\r\\n&lt;p&gt;This work was in part supported by grants from the Karolinska Institutet, Sweden.&lt;/p&gt;\\r\\n&lt;/ack&gt;\\r\\n&lt;ref-list&gt;\\r\\n&lt;title&gt;References&lt;/title&gt;\\r\\n&lt;ref id=\\&quot;B1\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Adamski&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Godman&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Ofierska-Sujkowska&lt;/surname&gt; &lt;given-names&gt;G.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Osinska&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Herholz&lt;/surname&gt; &lt;given-names&gt;H.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Wendykowska&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2010&lt;/year&gt;). &lt;article-title&gt;Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers&lt;/article-title&gt;. &lt;source&gt;BMC Health Serv. Res&lt;/source&gt;. &lt;volume&gt;10&lt;/volume&gt;:&lt;fpage&gt;153&lt;/fpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1186/1472-6963-10-153&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;20529296&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B1b\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;collab&gt;Arznei Vernunft&lt;/collab&gt;&lt;/person-group&gt; (&lt;year&gt;2014&lt;/year&gt;). &lt;source&gt;Antikoagulantien und Pl&amp;#x000E4;ttchen - funktionshemmer&lt;/source&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://www.arzneiundvernunft.at/uploads/20140225_Leitlinie_Antikoagulantien_211_DE.pdf\\&quot;&gt;http://www.arzneiundvernunft.at/uploads/20140225_Leitlinie_Antikoagulantien_211_DE.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B1a\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Barry&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;New oral anticoagulants for non-valvular atrial fibrillation &amp;#x02013; safety issues&lt;/article-title&gt;. &lt;source&gt;Ir. Med. J&lt;/source&gt;. &lt;volume&gt;106&lt;/volume&gt;, &lt;fpage&gt;69&lt;/fpage&gt;. &lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;23951972&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B2a\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Carley&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Griesbach&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Larson&lt;/surname&gt; &lt;given-names&gt;T.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Krueger&lt;/surname&gt; &lt;given-names&gt;K.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2014&lt;/year&gt;). &lt;article-title&gt;Assessment of Dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice&lt;/article-title&gt;. &lt;source&gt;Am. J. Cardiol&lt;/source&gt;. &lt;volume&gt;113&lt;/volume&gt;, &lt;fpage&gt;650&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;664&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1016/j.amjcard.2013.11.008&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;24484861&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B2\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Civaner&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;article-title&gt;Sale strategies of pharmaceutical companies in a &amp;#x02018;pharmerging&amp;#x02019; country: the problems will not improve if the gaps remain&lt;/article-title&gt;. &lt;source&gt;Health Policy&lt;/source&gt; &lt;volume&gt;106&lt;/volume&gt;, &lt;fpage&gt;25&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;32&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1016/j.healthpol.2012.05.006&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;22682762&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B3\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Davidson&lt;/surname&gt; &lt;given-names&gt;T.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Husberg&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Janzon&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Oldgren&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Levin&lt;/surname&gt; &lt;given-names&gt;L. &amp;#x000C5;.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden&lt;/article-title&gt;. &lt;source&gt;Eur. Heart J&lt;/source&gt;. &lt;volume&gt;34&lt;/volume&gt;, &lt;fpage&gt;177&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;183&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1093/eurheartj/ehs157&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;22733833&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B4\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;collab&gt;European Medicines Agency (EMA).&lt;/collab&gt;&lt;/person-group&gt; (&lt;year&gt;2011&lt;/year&gt;). &lt;source&gt;Update on Safety of Pradaxa&lt;/source&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://www.ema.europa.eu/ema/index.jsp?curl&amp;#x0003D;pages/news_and_events/news/2011/11/news_detail_001390.jsp&amp;#x00026;mid&amp;#x0003D;WC0b01ac058004d5c1\\&quot;&gt;http://www.ema.europa.eu/ema/index.jsp?curl&amp;#x0003D;pages/news_and_events/news/2011/11/news_detail_001390.jsp&amp;#x00026;mid&amp;#x0003D;WC0b01ac058004d5c1&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B5\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;collab&gt;Evaluate Pharma.&lt;/collab&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;source&gt;Surveying Tomorrow&amp;#x00027;s BioPharma Landscape - The NASDAQ Biotech Index Up Close. 2012&lt;/source&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://info.evaluatepharma.com/rs/evaluatepharmaltd/images/EvaluatePharma_NBI_Up_Close_2012.pdf\\&quot;&gt;http://info.evaluatepharma.com/rs/evaluatepharmaltd/images/EvaluatePharma_NBI_Up_Close_2012.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B6\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Ferrario&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Kanavos&lt;/surname&gt; &lt;given-names&gt;P.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;source&gt;Managed Entry Agreements for Pharmaceuticals: The European Experience&lt;/source&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf\\&quot;&gt;http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B7\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Forslund&lt;/surname&gt; &lt;given-names&gt;T.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Wettermark&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;W&amp;#x000E4;ndell&lt;/surname&gt; &lt;given-names&gt;P.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;von Euler&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Hasselstr&amp;#x000F6;m&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Hjemdahl&lt;/surname&gt; &lt;given-names&gt;P.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system&lt;/article-title&gt;. &lt;source&gt;Int. J. Cardiol&lt;/source&gt;. &lt;volume&gt;170&lt;/volume&gt;, &lt;fpage&gt;208&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;214&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1016/j.ijcard.2013.10.063&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;24239153&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B8\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Fritz&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Cleland&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2003&lt;/year&gt;). &lt;article-title&gt;Effectiveness versus efficacy: more than a debate over language&lt;/article-title&gt;. &lt;source&gt;J. Orthop. Sports Phys. Ther&lt;/source&gt;. &lt;volume&gt;33&lt;/volume&gt;, &lt;fpage&gt;163&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;165&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.2519/jospt.2003.33.4.163&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;12723672&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B9\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Garattini&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Bertele&lt;/surname&gt; &lt;given-names&gt;V.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Godman&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Haycox&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Wettermark&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Gustafsson&lt;/surname&gt; &lt;given-names&gt;L. L.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2008&lt;/year&gt;). &lt;article-title&gt;Enhancing the rational use of new medicines across European healthcare systems &amp;#x02013; a position paper&lt;/article-title&gt;. &lt;source&gt;Eur. J. Clin. Pharmacol&lt;/source&gt;. &lt;volume&gt;64&lt;/volume&gt;, &lt;fpage&gt;1137&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;1138&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1007/s00228-008-0537-z&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;18688606&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B10\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Godman&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Campbell&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Suh&lt;/surname&gt; &lt;given-names&gt;H. S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Finlayson&lt;/surname&gt; &lt;given-names&gt;A. E.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Bennie&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Gustafsson&lt;/surname&gt; &lt;given-names&gt;L. L.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries&lt;/article-title&gt;. &lt;source&gt;J. Health Technol. Assess&lt;/source&gt;. &lt;volume&gt;1&lt;/volume&gt;, &lt;fpage&gt;27&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;42&lt;/lpage&gt;.&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B11\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Godman&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Paterson&lt;/surname&gt; &lt;given-names&gt;K.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Malmstrom&lt;/surname&gt; &lt;given-names&gt;R.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Selke&lt;/surname&gt; &lt;given-names&gt;G.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Fagot&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;P, Mrak&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;article-title&gt;Improving the managed entry of new medicines: sharing experiences across Europe&lt;/article-title&gt;. &lt;source&gt;Exp. Rev. Pharmacoecon. Outcomes Res&lt;/source&gt;. &lt;volume&gt;12&lt;/volume&gt;, &lt;fpage&gt;439&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;441&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1586/erp.12.44&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;22971029&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B12\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Harper&lt;/surname&gt; &lt;given-names&gt;P.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Young&lt;/surname&gt; &lt;given-names&gt;L.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Merriman&lt;/surname&gt; &lt;given-names&gt;E.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;article-title&gt;Bleeding risk with dabigatran in the frail elderly&lt;/article-title&gt;. &lt;source&gt;N. Engl. J. Med&lt;/source&gt;. &lt;volume&gt;366&lt;/volume&gt;, &lt;fpage&gt;864&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;866&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1056/NEJMc1112874&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;22375994&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B12a\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;collab&gt;Irish Medicines Board.&lt;/collab&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;source&gt;Irish Medicines Board Drug safety Newsletter - October 2013. Novel Oral Anticoagulants (NOACs) and Risk of Bleeding - Reinforcement of Risk Minimisation Advice for Dabigatran (Pradaxa&amp;#x000AE;), Rivaroxaban (Xarelto&amp;#x000AE;) and Apixaban (Eliquis&amp;#x000AE;)&lt;/source&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://www.imb.ie/images/uploaded/documents/Drug%20Safety%20Newsletter%2056-Web%20version%20hyperlinked.pdf\\&quot;&gt;http://www.imb.ie/images/uploaded/documents/Drug%20Safety%20Newsletter%2056-Web%20version%20hyperlinked.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B13\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Joppi&lt;/surname&gt; &lt;given-names&gt;R.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Cinconze&lt;/surname&gt; &lt;given-names&gt;E.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Mezzalira&lt;/surname&gt; &lt;given-names&gt;L.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Pase&lt;/surname&gt; &lt;given-names&gt;D.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Poggiani&lt;/surname&gt; &lt;given-names&gt;C.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Rossi&lt;/surname&gt; &lt;given-names&gt;E.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study&lt;/article-title&gt;. &lt;source&gt;Eur. J. Intern. Med&lt;/source&gt;. &lt;volume&gt;24&lt;/volume&gt;, &lt;fpage&gt;318&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;323&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1016/j.ejim.2013.02.018&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;23528931&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B14\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Kaiser&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;article-title&gt;New cystic fibrosis drug offers hope, at a price&lt;/article-title&gt;. &lt;source&gt;Science&lt;/source&gt; &lt;volume&gt;335&lt;/volume&gt;:&lt;fpage&gt;645&lt;/fpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1126/science.335.6069.645&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;22323790&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B15\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Legrand&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Mateo&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Aibaud&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Ginisty&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Eftekhari&lt;/surname&gt; &lt;given-names&gt;P.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Huy&lt;/surname&gt; &lt;given-names&gt;P. T.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2011&lt;/year&gt;). &lt;article-title&gt;The use of dabigatran in elderly patients&lt;/article-title&gt;. &lt;source&gt;Arch. Intern. Med&lt;/source&gt;. &lt;volume&gt;8&lt;/volume&gt;, &lt;fpage&gt;432&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;439&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;21788545&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B16\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Malmstr&amp;#x000F6;m&lt;/surname&gt; &lt;given-names&gt;R. E.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Godman&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Diogene&lt;/surname&gt; &lt;given-names&gt;E.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Baumg&amp;#x000E4;rtel&lt;/surname&gt; &lt;given-names&gt;C.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Bennie&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Bishop&lt;/surname&gt; &lt;given-names&gt;I.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;Dabigatran - a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs&lt;/article-title&gt;. &lt;source&gt;Front. Pharmacol&lt;/source&gt;. &lt;volume&gt;4&lt;/volume&gt;:&lt;issue&gt;39&lt;/issue&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.3389/fphar.2013.00039&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;23717279&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B17\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Mannuci&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Nobil&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Garattini&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;article-title&gt;New drugs for thromboprophylaxis in atrial fibrillation&lt;/article-title&gt;. &lt;source&gt;Eur. J. Intern. Med&lt;/source&gt;. &lt;volume&gt;23&lt;/volume&gt;, &lt;fpage&gt;1&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;5&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1016/j.ejim.2011.11.007&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;22153522&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B18\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Marshall&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Fearon&lt;/surname&gt; &lt;given-names&gt;P.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Dawson&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Quinn&lt;/surname&gt; &lt;given-names&gt;T.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review&lt;/article-title&gt;. &lt;source&gt;Exp. Rev. Pharmacoecon. Outcomes Res&lt;/source&gt;. &lt;volume&gt;13&lt;/volume&gt;, &lt;fpage&gt;29&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;42&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1586/erp.12.79&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;23402443&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B18a\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;collab&gt;National Medicines Information Centre.&lt;/collab&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;source&gt;National Medicines Information Centre: Update on Oral Anticoagulation Therapy&lt;/source&gt; 8. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://www.imb.ie/images/uploaded/documents/Drug%20Safety%20Newsletter%2056-Web%20version%20hyperlinked.pdf\\&quot;&gt;http://www.imb.ie/images/uploaded/documents/Drug%20Safety%20Newsletter%2056-Web%20version%20hyperlinked.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B19\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;collab&gt;NICE.&lt;/collab&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;article-title&gt;&amp;#x0201C;Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation,&amp;#x0201D;&lt;/article-title&gt; in &lt;source&gt;NICE Technology Appraisal Guidance 249 March 2012&lt;/source&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://www.nice.org.uk/nicemedia/live/13677/58470/58470.pdf\\&quot;&gt;http://www.nice.org.uk/nicemedia/live/13677/58470/58470.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B20\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Pink&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Lane&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Pirmohamed&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Hughes&lt;/surname&gt; &lt;given-names&gt;D.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2011&lt;/year&gt;). &lt;article-title&gt;Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses&lt;/article-title&gt;. &lt;source&gt;BMJ&lt;/source&gt; &lt;volume&gt;343&lt;/volume&gt;:&lt;fpage&gt;d6333&lt;/fpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1136/bmj.d6333&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;22042753&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B21\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Reilly&lt;/surname&gt; &lt;given-names&gt;P. A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Lehr&lt;/surname&gt; &lt;given-names&gt;T.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Haertter&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Connolly&lt;/surname&gt; &lt;given-names&gt;S. J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Yusuf&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Eikelboom&lt;/surname&gt; &lt;given-names&gt;J. W.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2014&lt;/year&gt;). &lt;article-title&gt;The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)&lt;/article-title&gt;. &lt;source&gt;J. Am. Coll. Cardiol&lt;/source&gt;. &lt;volume&gt;63&lt;/volume&gt;, &lt;fpage&gt;321&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;328&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1016/j.jacc.2013.07.104&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;24076487&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B22\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;book\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Scott&lt;/surname&gt; &lt;given-names&gt;C. L.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;McTaggart&lt;/surname&gt; &lt;given-names&gt;S. A.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;) &lt;article-title&gt;&amp;#x0201C;Uptake and patterns of use of dabigatran and rivaroxaban in primary care in Scotland,&amp;#x0201D;&lt;/article-title&gt; in &lt;source&gt;American Society of Health System Pharmacists Midyear Meeting 2013&lt;/source&gt; (&lt;publisher-loc&gt;Orlando&lt;/publisher-loc&gt;) [Poster 1&amp;#x02013;256].&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B23\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;collab&gt;Scottish Medicines Consortium.&lt;/collab&gt;&lt;/person-group&gt; (&lt;year&gt;2008&lt;/year&gt;). &lt;article-title&gt;&amp;#x0201C;SMC Advice No. 466/08 dabigatran etexilate, 75mg and 110mg hard capsules (Pradaxa&amp;#x000AE;),&amp;#x0201D;&lt;/article-title&gt; in &lt;source&gt;Scottish Medicines Consortium. 09 June 2008&lt;/source&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://www.scottishmedicines.org/files/dabigatran_etexilate_Pradaxa_FINAL_May_2008_for_website.pdf\\&quot;&gt;http://www.scottishmedicines.org/files/dabigatran_etexilate_Pradaxa_FINAL_May_2008_for_website.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B24\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;collab&gt;Scottish Medicines Consortium.&lt;/collab&gt;&lt;/person-group&gt; (&lt;year&gt;2011&lt;/year&gt;). &lt;article-title&gt;&amp;#x0201C;SMC Advice No. 672/11 dabigatran etexilate 110mg and 150mg hard capsules (Pradaxa&amp;#x000AE;),&amp;#x0201D;&lt;/article-title&gt; in &lt;source&gt;Glasgow: Scottish Medicines Consortium&lt;/source&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://www.scottishmedicines.org/files/advice/dabigatran_Pradaxa_FINAL_August_2011_Amended_05.09.11_for_website.pdf\\&quot;&gt;http://www.scottishmedicines.org/files/advice/dabigatran_Pradaxa_FINAL_August_2011_Amended_05.09.11_for_website.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B25\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Spatz&lt;/surname&gt; &lt;given-names&gt;I.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;McGee&lt;/surname&gt; &lt;given-names&gt;N.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;source&gt;Speciality Pharmaceuticals. Complex New Drugs Hold Great Promise for People with Chronic and Life-Threatening Conditions. The Drugs are Also a Driver of Spending Growth&lt;/source&gt;. &lt;publisher-name&gt;Health Affairs Policy Brief&lt;/publisher-name&gt;. Available at online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_103.pdf\\&quot;&gt;http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_103.pdf&lt;/ext-link&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B26\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;web\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Thomas&lt;/surname&gt; &lt;given-names&gt;K.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2014&lt;/year&gt;). &lt;source&gt;Study of Drug for Blood Clots Caused a Stir, Records Show&lt;/source&gt;. &lt;publisher-name&gt;New York Times&lt;/publisher-name&gt;. Available online at: &lt;ext-link ext-link-type=\\&quot;uri\\&quot; xlink:href=\\&quot;http://www.nytimes.com/2014/02/06/business/study-of-blood-clot-drug-pradaxa-unnerved-its-maker-documents-suggest.html\\&quot;&gt;http://www.nytimes.com/2014/02/06/business/study-of-blood-clot-drug-pradaxa-unnerved-its-maker-documents-suggest.html&lt;/ext-link&gt; [Accessed March 2014]&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B27\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Thorne&lt;/surname&gt; &lt;given-names&gt;K.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Jayathissa&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Dee&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Briggs&lt;/surname&gt; &lt;given-names&gt;N.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Taylor&lt;/surname&gt; &lt;given-names&gt;J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Reid&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2014&lt;/year&gt;). &lt;article-title&gt;Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice&lt;/article-title&gt;. &lt;source&gt;Intern. Med. J&lt;/source&gt;. &lt;volume&gt;44&lt;/volume&gt;, &lt;fpage&gt;261&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;265&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1111/imj.12370&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;24405800&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B28\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Troncoso&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Diog&amp;#x000E8;ne&lt;/surname&gt; &lt;given-names&gt;E.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2014&lt;/year&gt;). &lt;article-title&gt;Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs&lt;/article-title&gt;. &lt;source&gt;Eur. J. Clin. Pharmacol&lt;/source&gt;. &lt;volume&gt;70&lt;/volume&gt;, &lt;fpage&gt;249&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;250&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1007/s00228-013-1593-6&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;24132558&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B29\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Wells&lt;/surname&gt; &lt;given-names&gt;K. B.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;1999&lt;/year&gt;). &lt;article-title&gt;Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research&lt;/article-title&gt;. &lt;source&gt;Am. J. Psychiatry&lt;/source&gt; &lt;volume&gt;156&lt;/volume&gt;, &lt;fpage&gt;5&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;10&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;9892291&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B30\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Wettermark&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Godman&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Jacobsson&lt;/surname&gt; &lt;given-names&gt;B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Haaijer-Ruskamp&lt;/surname&gt; &lt;given-names&gt;F.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2009&lt;/year&gt;). &lt;article-title&gt;Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences&lt;/article-title&gt;. &lt;source&gt;Appl. Health Econ. Health Policy&lt;/source&gt; &lt;volume&gt;7&lt;/volume&gt;, &lt;fpage&gt;137&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;147&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1007/BF03256147&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;19799468&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B30a\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Xu&lt;/surname&gt; &lt;given-names&gt;Y.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Holbrook&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Simpson&lt;/surname&gt; &lt;given-names&gt;C.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Dowlatshahi&lt;/surname&gt; &lt;given-names&gt;D.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Johnson&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;Prescribing patters of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis&lt;/article-title&gt;. &lt;source&gt;CMAJ Open&lt;/source&gt; &lt;volume&gt;1&lt;/volume&gt;, &lt;fpage&gt;E115&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;E119&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.9778/cmajo.20130032&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;/ref-list&gt;\\r\\n&lt;bio&gt;\\r\\n&lt;p&gt;&lt;inline-graphic xlink:href=\\&quot;fphar-05-00109-i0001.tif\\&quot;/&gt; &lt;bold&gt;Brian Godman&lt;/bold&gt;, works with health authorities and health insurance companies across continents analysing the influence of supply- and demand-side initiatives to enhance prescribing efficiency of both new and established drugs given continual pressure on resources. This includes developing new models to optimize the managed entry of new drugs based on pre-, peri- and post-launch activities and encouraging the prescribing of low costs multiple sourced products. The findings provide direction for the future, with countries increasingly learning from each other.&lt;/p&gt;\\r\\n&lt;/bio&gt;\\r\\n&lt;/back&gt;\\r\\n&lt;/article&gt;&quot; #&gt; #&gt; $data$data$`10.3389/feart.2015.00009` #&gt; [1] &quot;&lt;?xml version=\\&quot;1.0\\&quot; encoding=\\&quot;UTF-8\\&quot; standalone=\\&quot;no\\&quot;?&gt;\\r\\n&lt;!DOCTYPE article PUBLIC \\&quot;-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN\\&quot; \\&quot;journalpublishing.dtd\\&quot;&gt;\\r\\n&lt;article xmlns:mml=\\&quot;http://www.w3.org/1998/Math/MathML\\&quot; xmlns:xlink=\\&quot;http://www.w3.org/1999/xlink\\&quot; article-type=\\&quot;editorial\\&quot;&gt;\\r\\n&lt;front&gt;\\r\\n&lt;journal-meta&gt;\\r\\n&lt;journal-id journal-id-type=\\&quot;publisher-id\\&quot;&gt;Front. Earth Sci.&lt;/journal-id&gt;\\r\\n&lt;journal-title&gt;Frontiers in Earth Science&lt;/journal-title&gt;\\r\\n&lt;abbrev-journal-title abbrev-type=\\&quot;pubmed\\&quot;&gt;Front. Earth Sci.&lt;/abbrev-journal-title&gt;\\r\\n&lt;issn pub-type=\\&quot;epub\\&quot;&gt;2296-6463&lt;/issn&gt;\\r\\n&lt;publisher&gt;\\r\\n&lt;publisher-name&gt;Frontiers Media S.A.&lt;/publisher-name&gt;\\r\\n&lt;/publisher&gt;\\r\\n&lt;/journal-meta&gt;\\r\\n&lt;article-meta&gt;\\r\\n&lt;article-id pub-id-type=\\&quot;doi\\&quot;&gt;10.3389/feart.2015.00009&lt;/article-id&gt;\\r\\n&lt;article-categories&gt;\\r\\n&lt;subj-group subj-group-type=\\&quot;heading\\&quot;&gt;\\r\\n&lt;subject&gt;Earth Science&lt;/subject&gt;\\r\\n&lt;subj-group&gt;\\r\\n&lt;subject&gt;Specialty Grand Challenge&lt;/subject&gt;\\r\\n&lt;/subj-group&gt;\\r\\n&lt;/subj-group&gt;\\r\\n&lt;/article-categories&gt;\\r\\n&lt;title-group&gt;\\r\\n&lt;article-title&gt;The challenges and opportunities for research in paleontology for the next decade&lt;/article-title&gt;\\r\\n&lt;/title-group&gt;\\r\\n&lt;contrib-group&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot; corresp=\\&quot;yes\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Reisz&lt;/surname&gt; &lt;given-names&gt;Robert R.&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff1\\&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;xref ref-type=\\&quot;author-notes\\&quot; rid=\\&quot;fn001\\&quot;&gt;&lt;sup&gt;&amp;#x0002A;&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/103206\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;contrib contrib-type=\\&quot;author\\&quot;&gt;\\r\\n&lt;name&gt;&lt;surname&gt;Sues&lt;/surname&gt; &lt;given-names&gt;Hans-Dieter&lt;/given-names&gt;&lt;/name&gt;\\r\\n&lt;xref ref-type=\\&quot;aff\\&quot; rid=\\&quot;aff2\\&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;\\r\\n&lt;uri xlink:href=\\&quot;http://community.frontiersin.org/people/u/130757\\&quot;/&gt;\\r\\n&lt;/contrib&gt;\\r\\n&lt;/contrib-group&gt;\\r\\n&lt;aff id=\\&quot;aff1\\&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;institution&gt;Department of Biology, University of Toronto Mississauga&lt;/institution&gt; &lt;country&gt;Mississauga, ON, Canada&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;aff id=\\&quot;aff2\\&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;institution&gt;Department of Paleobiology, National Museum of Natural History, Smithsonian Institution&lt;/institution&gt; &lt;country&gt;Washington, DC, USA&lt;/country&gt;&lt;/aff&gt;\\r\\n&lt;author-notes&gt;\\r\\n&lt;fn fn-type=\\&quot;edited-by\\&quot;&gt;&lt;p&gt;Edited by: Hugo F. R. Bucher, University of Z&amp;#x000FC;rich, Switzerland&lt;/p&gt;&lt;/fn&gt;\\r\\n&lt;fn fn-type=\\&quot;edited-by\\&quot;&gt;&lt;p&gt;Reviewed by: Peter D. Roopnarine, California Academy of Sciences, USA&lt;/p&gt;&lt;/fn&gt;\\r\\n&lt;fn fn-type=\\&quot;corresp\\&quot; id=\\&quot;fn001\\&quot;&gt;&lt;p&gt;&amp;#x0002A;Correspondence: Robert R. Reisz, &lt;email&gt;robert.reisz&amp;#x00040;utoronto.ca&lt;/email&gt;&lt;/p&gt;&lt;/fn&gt;\\r\\n&lt;fn fn-type=\\&quot;other\\&quot; id=\\&quot;fn002\\&quot;&gt;&lt;p&gt;This article was submitted to Paleontology, a section of the journal Frontiers in Earth Science&lt;/p&gt;&lt;/fn&gt;\\r\\n&lt;/author-notes&gt;\\r\\n&lt;pub-date pub-type=\\&quot;epub\\&quot;&gt;\\r\\n&lt;day&gt;10&lt;/day&gt;\\r\\n&lt;month&gt;03&lt;/month&gt;\\r\\n&lt;year&gt;2015&lt;/year&gt;\\r\\n&lt;/pub-date&gt;\\r\\n&lt;pub-date pub-type=\\&quot;collection\\&quot;&gt;\\r\\n&lt;year&gt;2015&lt;/year&gt;\\r\\n&lt;/pub-date&gt;\\r\\n&lt;volume&gt;3&lt;/volume&gt;\\r\\n&lt;elocation-id&gt;9&lt;/elocation-id&gt;\\r\\n&lt;history&gt;\\r\\n&lt;date date-type=\\&quot;received\\&quot;&gt;\\r\\n&lt;day&gt;13&lt;/day&gt;\\r\\n&lt;month&gt;10&lt;/month&gt;\\r\\n&lt;year&gt;2014&lt;/year&gt;\\r\\n&lt;/date&gt;\\r\\n&lt;date date-type=\\&quot;accepted\\&quot;&gt;\\r\\n&lt;day&gt;22&lt;/day&gt;\\r\\n&lt;month&gt;02&lt;/month&gt;\\r\\n&lt;year&gt;2015&lt;/year&gt;\\r\\n&lt;/date&gt;\\r\\n&lt;/history&gt;\\r\\n&lt;permissions&gt;\\r\\n&lt;copyright-statement&gt;Copyright &amp;#x000A9; 2015 Reisz and Sues.&lt;/copyright-statement&gt;\\r\\n&lt;copyright-year&gt;2015&lt;/copyright-year&gt;\\r\\n&lt;license license-type=\\&quot;open-access\\&quot; xlink:href=\\&quot;http://creativecommons.org/licenses/by/4.0/\\&quot;&gt;&lt;p&gt;This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.&lt;/p&gt;\\r\\n&lt;/license&gt;\\r\\n&lt;/permissions&gt;\\r\\n&lt;kwd-group&gt;\\r\\n&lt;kwd&gt;paleontology&lt;/kwd&gt;\\r\\n&lt;kwd&gt;interdisciplinary science&lt;/kwd&gt;\\r\\n&lt;kwd&gt;paleobiology&lt;/kwd&gt;\\r\\n&lt;kwd&gt;evolution&lt;/kwd&gt;\\r\\n&lt;kwd&gt;earth history&lt;/kwd&gt;\\r\\n&lt;/kwd-group&gt;\\r\\n&lt;counts&gt;\\r\\n&lt;fig-count count=\\&quot;0\\&quot;/&gt;\\r\\n&lt;table-count count=\\&quot;0\\&quot;/&gt;\\r\\n&lt;equation-count count=\\&quot;0\\&quot;/&gt;\\r\\n&lt;ref-count count=\\&quot;15\\&quot;/&gt;\\r\\n&lt;page-count count=\\&quot;3\\&quot;/&gt;\\r\\n&lt;word-count count=\\&quot;2336\\&quot;/&gt;\\r\\n&lt;/counts&gt;\\r\\n&lt;/article-meta&gt;\\r\\n&lt;/front&gt;\\r\\n&lt;body&gt;\\r\\n&lt;p&gt;Since the recognition of fossils as remnants of once-living organisms by early polymaths such as Leonardo da Vinci and Nicholas Steno, paleontology has become the clearest window into the long history of life on Earth. During much of the nineteenth and twentieth centuries, paleontology was primarily an observational science, focused on the discovery, naming, and description of fossil plants and animals. Of particular note, early discoveries of dinosaurs and other large extinct animals such as proboscideans brought the field of paleontology to the attention of the general public, and the fascination with these strange creatures of the past has continued to grow since that time. A parallel line of inquiry has developed through the use of fossils for working out the succession and relative ages of sedimentary rocks worldwide, establishing a critical link to other earth sciences and the practical utility of palaeontological research. However, especially following the publication of Darwin&amp;#x00027;s &lt;italic&gt;magnum opus&lt;/italic&gt;, paleontologists became increasingly interested in understanding the significance of fossils for reconstructing the history of Life through time. Starting early in the twentieth century, many researchers focused on interpreting extinct organisms as once-living beings and their ecological relationships with their environment and to each other. It is therefore with the acceptance of such processes as origination, evolution and extinction within local, regional and global frameworks, that paleontology really entered the modern era, with researchers studying the evolution of particular groups of organisms and communities through time, and their interactions within and with the biosphere. Thus, paleontology has come to represent a unique field, providing deep-time perspectives on the biological and geological processes of our planet.&lt;/p&gt;\\r\\n&lt;p&gt;The overall purpose of the paleontological section of this journal is to promote excellence in this area of research, focus on topics of particular interest, and publish studies that will carry the field forward in the twenty-first century.&lt;/p&gt;\\r\\n&lt;p&gt;The study of the diversity and distribution of extinct life forms retains a central role in paleontology, much like work on the diversity of extant organisms in biology. Although this core activity is often denigrated as an intellectually inferior exercise by researchers primarily interested in understanding large-scale patterns and processes of evolution, the latter studies stand and fall on the quality of the underlying primary morphological and taxonomic data. Fossils are unique in documenting changes over long intervals of time, and frequently have features and combinations of features not found in extant taxa (Edgecombe, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B4\\&quot;&gt;2010&lt;/xref&gt;). They also establish the spatial and temporal distribution of organisms. Intense reconnaissance efforts across the globe continue to uncover vast numbers of new or little-known extinct species (Caron et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B1\\&quot;&gt;2014&lt;/xref&gt;), some of which represent novel body plans. Such studies form the bedrock of the discipline, and its support through this journal is critical for the continued vitality of the discipline. However, the nuts-and-bolts approach to this kind of research is already being covered by the specialty journals for each sub-discipline. The Frontier aspect of documenting the history of life on Earth is tied more to the need to integrate the various sub-disciplines of paleontology into the broader study of the fossil record from evolutionary and ecological perspectives (Gill et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B7\\&quot;&gt;2014&lt;/xref&gt;). Increasingly, paleontologists are studying entire communities of extinct organisms, permitting more holistic approaches to understanding the ecosystems in which particular life forms or group of organisms lived and the conditions under which they died and were preserved. This approach to the study of the fossil record has become truly interdisciplinary, drawing on a wide range of physical and biological sciences.&lt;/p&gt;\\r\\n&lt;p&gt;Since more than 99 percent of the species that ever lived on this planet are already extinct (Raup, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B11\\&quot;&gt;1986&lt;/xref&gt;), the number of fossil organisms yet to be discovered remains vast. Ever since Darwin there have been many discussions concerning the relative completeness of the fossil record over the years but numerous recent studies have argued that the quality of the record has been improving (e.g., Wills et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B15\\&quot;&gt;2008&lt;/xref&gt;). Although many aspects of plant and animal evolution have indeed been clarified in recent decades, countless unresolved questions remain. Frequently new fossils (and new approaches to their study) generate more questions than answers. There is a continuing need to integrate new discoveries and new data into the overall evolutionary picture, and examine how they improve our understanding of the evolutionary processes that led to extant life forms and the communities that they form. Thus, major events in the history of life, including the origin, adaptive radiation, and extinction of the major clades are long-term trends that can only be fully understood through the deep-time perspective provided by paleontology. This continues to be a major frontier of paleontology. Recent research on the origin and early diversification of tetrapods provides a particularly impressive example (Clack, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B2\\&quot;&gt;2009&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Phylogenetic research on extant life forms is increasingly based predominantly on molecular data. Dramatic advances in technology have greatly facilitated acquisition and analysis of genomic sequences and other biomolecular information. Indeed, a few researchers have even completely dismissed the relevance of morphological data for phylogeny reconstruction. However, present-day organisms only represent a vanishingly small percentage of all life forms that ever existed on Earth, and most fossils do not preserve biomolecules. Thus, meaningful studies of total biodiversity must involve reciprocal illumination, repeatedly comparing and testing hypotheses generated from molecular data by comparison with morphological information from both extant and extinct species.&lt;/p&gt;\\r\\n&lt;p&gt;Patterns of diversification and extinction, as documented by the fossil record, not only illustrate the history of the biosphere but also offer insights into possible outcomes of major environmental changes in the future. Many researchers are now exploring the biological consequences of the five mass extinctions during the last 540 million years or so and the causative physical processes. This is a particularly relevant field of inquiry at a time when there is increasing concern about the impact of anthropogenic environmental change.&lt;/p&gt;\\r\\n&lt;p&gt;In recent years the issue of climate change has received much attention from the scientific community and the general public. There is general agreement among researchers that climate change profoundly affects biological systems, but it is less well-understood how ecosystems and individual species respond to such changes. Both of these are areas in which paleontological research can have a major impact. Palaeoclimatic modeling is now possible through the integration of numerous sources of geological, biological, and chemical information, such as stable isotopes. A greater understanding of the relationship between climate change and the diversification and extinction of ancient organisms and communities provides case studies for assessing future changes in the biosphere (McInerney and Wing, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B9\\&quot;&gt;2011&lt;/xref&gt;). In looking at the present environmental crisis data on the time frames and rates of changes in the geological past are vitally important for evaluating possible responses of the biosphere to climate changes.&lt;/p&gt;\\r\\n&lt;p&gt;The strength of paleontology is the unique contributions it can make to the understanding of the history of life, like the discoveries of major groups of organisms previously unknown to science, novel body plans, studies of rates of speciation and extinction, and the origins of and subsequent changes in marine and continental ecosystems. The integration of the information provided by the fossil record with geological data will continue to provide critical new insights into such events in the history of life on earth (Dunne et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B3\\&quot;&gt;2014&lt;/xref&gt;). This journal would therefore like to publish papers that integrate geological and palaeobiological data for testing hypotheses of major extinction events.&lt;/p&gt;\\r\\n&lt;p&gt;Other major challenges facing the discipline include keeping up with the revolutionary changes that are occurring in the other natural sciences, and taking full advantage of those changes for maintaining paleontology&amp;#x00027;s role as the primary interpreter of the history of life on Earth. Cutting-edge paleontological research now includes computer modeling for testing hypotheses concerning aspects of the biology of extinct taxa when no extant relatives or even close analogs exist. One elegant example is testing locomotory abilities in large, bipedal non-avian dinosaurs (Hutchinson, &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B8\\&quot;&gt;2004&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;In the last three decades, CT scanning and related imaging techniques (like neutron scanning) have opened up exciting new avenues for non-destructive investigations of the structure of fossils. Initially these studies were conducted on medical CT units with relatively low resolution, but recently micro- and even nano-level imaging has become possible (Sanchez et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B14\\&quot;&gt;2012&lt;/xref&gt;). Histology has also become a major tool for studying the hard tissues of fossils (Reisz et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B12\\&quot;&gt;2013&lt;/xref&gt;). In particular, this approach has facilitated studies of growth patterns and reconstructions of metabolic rates in extinct vertebrates (Padian et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B10\\&quot;&gt;2004&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;Recent advances in our understanding of the relationship between development and evolution in extant animals have provided a new area of research. For example, understanding of developmental regulation based on genomics combined with geochemical data for palaeoenvironmental reconstruction has shed much light on the initial diversification of multicellular animals (Erwin et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B5\\&quot;&gt;2011&lt;/xref&gt;). It is now possible to test, for the first time, hypotheses of development and growth in extinct organisms by using developmental data from extant forms. Cutting-edge research in this area includes investigations of past evolutionary events with molecular and developmental studies on living organisms (Rota-Stabelli et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B13\\&quot;&gt;2011&lt;/xref&gt;; Gehrke et al., &lt;xref ref-type=\\&quot;bibr\\&quot; rid=\\&quot;B6\\&quot;&gt;2015&lt;/xref&gt;).&lt;/p&gt;\\r\\n&lt;p&gt;The overarching challenge to paleontology in the coming decades is the integration of palaeobiology with evolutionary biology, but with a good understanding of what evolutionary questions can be addressed within the context of the fossil record. Balance is key, because reductionist explanations of major evolutionary events do not conform to current standards of modern evolutionary biology. It is in many ways counterproductive to propose simple hypotheses based on single causal relationships between biological or geological events and such complex major phenomena as the co-evolution of terrestrial plants and animals or major extinction events. Modern evolutionary biology has revealed the complex interactions between biological and earth systems that defy simple explanations. Bridging the understanding of macro- and microevolutionary processes has been a historical challenge for paleontologists and evolutionary biologists and should continue to be the primary goal for students in both research areas.&lt;/p&gt;\\r\\n&lt;sec&gt;\\r\\n&lt;title&gt;Conflict of interest statement&lt;/title&gt;\\r\\n&lt;p&gt;The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.&lt;/p&gt;&lt;/sec&gt;\\r\\n&lt;/body&gt;\\r\\n&lt;back&gt;\\r\\n&lt;ack&gt;\\r\\n&lt;p&gt;We thank Prof. H. Bucher and Dr. Peter D. Roopnarine for their helpful comments on a draft of this editorial.&lt;/p&gt;\\r\\n&lt;/ack&gt;\\r\\n&lt;ref-list&gt;\\r\\n&lt;title&gt;References&lt;/title&gt;\\r\\n&lt;ref id=\\&quot;B1\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Caron&lt;/surname&gt; &lt;given-names&gt;J.-B.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Gaines&lt;/surname&gt; &lt;given-names&gt;R. R.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Aria&lt;/surname&gt; &lt;given-names&gt;C.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Mangano&lt;/surname&gt; &lt;given-names&gt;M. G.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Streng&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2014&lt;/year&gt;). &lt;article-title&gt;A new phyllopod bed-like assemblage from the Burgess Shale of the Canadian Rockies&lt;/article-title&gt;. &lt;source&gt;Nat. Commun&lt;/source&gt;. &lt;volume&gt;5&lt;/volume&gt;:&lt;fpage&gt;3210&lt;/fpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1038/ncomms4210&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;24513643&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B2\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Clack&lt;/surname&gt; &lt;given-names&gt;J. A.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2009&lt;/year&gt;). &lt;article-title&gt;The fin to limb transition: new data, interpretations, and hypotheses from paleontology and developmental biology&lt;/article-title&gt;. &lt;source&gt;Annu. Rev. Earth Planet. Sci&lt;/source&gt;. &lt;volume&gt;37&lt;/volume&gt;, &lt;fpage&gt;163&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;179&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1146/annurev.earth.36.031207.124146&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B3\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Dunne&lt;/surname&gt; &lt;given-names&gt;J. A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Labandeira&lt;/surname&gt; &lt;given-names&gt;C. C.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Williams&lt;/surname&gt; &lt;given-names&gt;R. J.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2014&lt;/year&gt;). &lt;article-title&gt;Highly resolved early Eocene food webs show development of modern trophic structure after the end-Cretaceous extinction&lt;/article-title&gt;. &lt;source&gt;Proc. R. Soc. B&lt;/source&gt; &lt;volume&gt;281&lt;/volume&gt;:&lt;fpage&gt;20133280&lt;/fpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1098/rspb.2013.3280&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;24648225&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B4\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Edgecombe&lt;/surname&gt; &lt;given-names&gt;G. D.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2010&lt;/year&gt;). &lt;article-title&gt;Arthropod phylogeny: an overview from the perspectives of morphology, molecular data and the fossil record&lt;/article-title&gt;. &lt;source&gt;Arthropod Struct. Dev&lt;/source&gt;. &lt;volume&gt;39&lt;/volume&gt;, &lt;fpage&gt;74&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;87&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1016/j.asd.2009.10.002&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;19854297&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B5\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Erwin&lt;/surname&gt; &lt;given-names&gt;D. H.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Laflamme&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Tweedt&lt;/surname&gt; &lt;given-names&gt;S. M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Sperling&lt;/surname&gt; &lt;given-names&gt;E. A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Pisani&lt;/surname&gt; &lt;given-names&gt;D.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Peterson&lt;/surname&gt; &lt;given-names&gt;K. J.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2011&lt;/year&gt;). &lt;article-title&gt;The Cambrian conundrum: early divergence and later ecological success in the early history of animals&lt;/article-title&gt;. &lt;source&gt;Science&lt;/source&gt; &lt;volume&gt;334&lt;/volume&gt;, &lt;fpage&gt;1091&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;1097&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1126/science.1206375&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;22116879&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B6\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Gehrke&lt;/surname&gt; &lt;given-names&gt;A. R.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Schneider&lt;/surname&gt; &lt;given-names&gt;I.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;de la Calle-Mustienes&lt;/surname&gt; &lt;given-names&gt;E.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Tena&lt;/surname&gt; &lt;given-names&gt;J. J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Gomez-Marin&lt;/surname&gt; &lt;given-names&gt;C.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Chandran&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2015&lt;/year&gt;). &lt;article-title&gt;Deep conservation of wrist and digit enhancers in fish&lt;/article-title&gt;. &lt;source&gt;Proc. Natl. Acad. Sci. U.S.A&lt;/source&gt;. &lt;volume&gt;112&lt;/volume&gt;, &lt;fpage&gt;803&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;808&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1073/pnas.1420208112&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;25535365&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B7\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Gill&lt;/surname&gt; &lt;given-names&gt;P. G.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Purnell&lt;/surname&gt; &lt;given-names&gt;M. A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Crumpton&lt;/surname&gt; &lt;given-names&gt;N.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Brown&lt;/surname&gt; &lt;given-names&gt;K. R.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Gostling&lt;/surname&gt; &lt;given-names&gt;N. J.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Stampanoni&lt;/surname&gt; &lt;given-names&gt;M.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2014&lt;/year&gt;). &lt;article-title&gt;Dietary specializations and diversity in feeding ecology of the earliest stem mammals&lt;/article-title&gt;. &lt;source&gt;Nature&lt;/source&gt; &lt;volume&gt;512&lt;/volume&gt;, &lt;fpage&gt;303&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;305&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1038/nature13622&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;25143112&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B8\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Hutchinson&lt;/surname&gt; &lt;given-names&gt;J. R.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2004&lt;/year&gt;). &lt;article-title&gt;Biomedical modeling and sensitivity analysis of bipedal running ability. II. Extinct taxa&lt;/article-title&gt;. &lt;source&gt;J. Morphol&lt;/source&gt;. &lt;volume&gt;262&lt;/volume&gt;, &lt;fpage&gt;441&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;461&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1002/jmor.10240&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;15352202&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B9\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;McInerney&lt;/surname&gt; &lt;given-names&gt;F. A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Wing&lt;/surname&gt; &lt;given-names&gt;S. L.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2011&lt;/year&gt;). &lt;article-title&gt;The Paleocene-Eocene Thermal Maximum: a perturbation of carbon cycle, climate, and biosphere with implications for the future&lt;/article-title&gt;. &lt;source&gt;Annu. Rev. Earth Planet. Sci&lt;/source&gt;. &lt;volume&gt;39&lt;/volume&gt;, &lt;fpage&gt;489&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;516&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1146/annurev-earth-040610-133431&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B10\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Padian&lt;/surname&gt; &lt;given-names&gt;K.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Horner&lt;/surname&gt; &lt;given-names&gt;J. R.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;de Ricql&amp;#x000E8;s&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2004&lt;/year&gt;). &lt;article-title&gt;Growth in small dinosaurs and pterosaurs: the evolution of archosaurian growth strategies&lt;/article-title&gt;. &lt;source&gt;J. Vert. Paleontol&lt;/source&gt;. &lt;volume&gt;25&lt;/volume&gt;, &lt;fpage&gt;555&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;571&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1671/0272-4634(2004)024[0555:GISDAP]2.0.CO;2&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B11\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Raup&lt;/surname&gt; &lt;given-names&gt;D. M.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;1986&lt;/year&gt;). &lt;article-title&gt;Biological extinction in earth history&lt;/article-title&gt;. &lt;source&gt;Science&lt;/source&gt; &lt;volume&gt;231&lt;/volume&gt;, &lt;fpage&gt;1528&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;1533&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1126/science.11542058&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;11542058&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B12\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Reisz&lt;/surname&gt; &lt;given-names&gt;R. R.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Huang&lt;/surname&gt; &lt;given-names&gt;T.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Roberts&lt;/surname&gt; &lt;given-names&gt;E. M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Peng&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Sullivan&lt;/surname&gt; &lt;given-names&gt;C.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Stein&lt;/surname&gt; &lt;given-names&gt;K.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2013&lt;/year&gt;). &lt;article-title&gt;Embryology of Early Jurassic dinosaur from China with evidence of preserved organic remains&lt;/article-title&gt;. &lt;source&gt;Nature&lt;/source&gt; &lt;volume&gt;496&lt;/volume&gt;, &lt;fpage&gt;210&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;214&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1038/nature11978&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;23579680&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B13\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Rota-Stabelli&lt;/surname&gt; &lt;given-names&gt;O.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Campbell&lt;/surname&gt; &lt;given-names&gt;L.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Brinkmann&lt;/surname&gt; &lt;given-names&gt;H.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Edgecombe&lt;/surname&gt; &lt;given-names&gt;G. D.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Longhorn&lt;/surname&gt; &lt;given-names&gt;S. T.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Peterson&lt;/surname&gt; &lt;given-names&gt;K. J.&lt;/given-names&gt;&lt;/name&gt; &lt;etal/&gt;&lt;/person-group&gt;. (&lt;year&gt;2011&lt;/year&gt;). &lt;article-title&gt;A congruent solution to arthropod phylogeny: phylogenomics, microRNAs and morphology support monophyletic Mandibulata&lt;/article-title&gt;. &lt;source&gt;Proc. Biol. Sci&lt;/source&gt;. &lt;volume&gt;278&lt;/volume&gt;, &lt;fpage&gt;298&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;306&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1098/rspb.2010.0590&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;20702459&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B14\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Sanchez&lt;/surname&gt; &lt;given-names&gt;S.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Ahlberg&lt;/surname&gt; &lt;given-names&gt;P. E.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Trinajstic&lt;/surname&gt; &lt;given-names&gt;K. M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Mirone&lt;/surname&gt; &lt;given-names&gt;A.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2012&lt;/year&gt;). &lt;article-title&gt;Three-dimensional synchrotron virtual paleohistology: a new insight into the world of fossil bone microstructures&lt;/article-title&gt;. &lt;source&gt;Microsc. Microanal&lt;/source&gt;. &lt;volume&gt;18&lt;/volume&gt;, &lt;fpage&gt;1095&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;1105&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1017/S1431927612001079&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;23026256&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;ref id=\\&quot;B15\\&quot;&gt;\\r\\n&lt;citation citation-type=\\&quot;journal\\&quot;&gt;&lt;person-group person-group-type=\\&quot;author\\&quot;&gt;&lt;name&gt;&lt;surname&gt;Wills&lt;/surname&gt; &lt;given-names&gt;M. A.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Barrett&lt;/surname&gt; &lt;given-names&gt;P. M.&lt;/given-names&gt;&lt;/name&gt; &lt;name&gt;&lt;surname&gt;Heathcote&lt;/surname&gt; &lt;given-names&gt;J. F.&lt;/given-names&gt;&lt;/name&gt;&lt;/person-group&gt; (&lt;year&gt;2008&lt;/year&gt;). &lt;article-title&gt;The modified gap excess ratio (GER&lt;sup&gt;&amp;#x0002A;&lt;/sup&gt;) and the stratigraphic congruence of dinosaur phylogenies&lt;/article-title&gt;. &lt;source&gt;Syst. Biol&lt;/source&gt;. &lt;volume&gt;57&lt;/volume&gt;, &lt;fpage&gt;891&lt;/fpage&gt;&amp;#x02013;&lt;lpage&gt;904&lt;/lpage&gt;. &lt;pub-id pub-id-type=\\&quot;doi\\&quot;&gt;10.1080/10635150802570809&lt;/pub-id&gt;&lt;pub-id pub-id-type=\\&quot;pmid\\&quot;&gt;19085331&lt;/pub-id&gt;&lt;/citation&gt;\\r\\n&lt;/ref&gt;\\r\\n&lt;/ref-list&gt;\\r\\n&lt;/back&gt;\\r\\n&lt;/article&gt;\\r\\n&quot; #&gt; #&gt; attr(,&quot;format&quot;) #&gt; [1] &quot;xml&quot; #&gt; #&gt; #&gt; $opts #&gt; $opts$dois #&gt; [1] &quot;10.3389/fphar.2014.00109&quot; &quot;10.3389/feart.2015.00009&quot; #&gt; #&gt; $opts$basepath #&gt; [1] &quot;/Users/sckott/Library/Caches/R/fulltext&quot; #&gt; #&gt; $opts$type #&gt; [1] &quot;xml&quot; "],
["chunks.html", "Chapter 8 Chunks", " Chapter 8 Chunks chunks "],
["supplementary.html", "Chapter 9 Supplementary", " Chapter 9 Supplementary supplementary "],
["use-cases.html", "Chapter 10 Use cases", " Chapter 10 Use cases use cases "],
["literature.html", "Chapter 11 Literature", " Chapter 11 Literature Here is a review of existing methods. "]
]
